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Introduction 
Introduction 
 
Epidemiology of heart failure 
Coronary artery disease is still one of the leading causes of morbidity and mortality in 
western society1. In The Netherlands (www.hartstichting.nl) 32% of all deaths are 
caused by heart and vascular diseases. This translates in more than 44.000 people per 
year, of which 24% died after a myocardial infarction. In The Netherlands in 2005, 66 
patients per day were hospitalized due to a myocardial infarction of which only 11% 
died during hospitalization. In contrast, in 1972 21% of the hospitalized patients died 
in the hospital after a myocardial infarction. The incidence of a myocardial infarction 
in The Netherlands is estimated at 2.3 per 1000 persons.  
Myocardial infarction causes abrupt loss of left ventricular synergy and global 
dysfunction. After myocardial infarction, the decreased left ventricular function 
results in a decreased ejection fraction and cardiac output due to the loss of 
cardiomyocytes. Rapid neurohumoral activation and early ventricular chamber 
dilatation contribute to restoring stroke volume despite the depressed ejection 
fraction. Continued neurohumoral activation provokes late remodeling of the remote 
non-infarcted myocardium, characterized by a progressively increasing left ventricular 
volume/mass ratio that leads to further remodeling. Due to dilation caused by 
remodeling, end systolic and diastolic volumes are increased after infarction.  
Heart failure is a progressive disorder of left ventricular remodeling. Heart 
failure from post-infarction remodeling due to the dysfunctional scar tissue causes 
continuous abnormal loading conditions. Left ventricular remodeling is a dynamic 
process that is driven by a number of factors. During remodeling, the left ventricle 
becomes dilated, changes shape, and undergoes morphologic and physiologic 
alterations at the cellular level2. This results eventually in depressed left ventricular 
contractility. Pathologically, there is extensive fibrosis with abnormally structured 
myocardial cells that are disarrayed2. Apoptosis (programmed cell death) becomes 
more active, resulting in additional loss of myocardial cells. It is the combination of 
these pathologic changes that deforms the structure of the heart and impairs the 
dynamics of the left ventricle.  
Patients with coronary artery disease, who survive a myocardial infarction, are 
at an increased risk of developing heart failure. The extent of left ventricular systolic 
and diastolic dysfunction is associated with clinical symptoms and cardiovascular 
mortality. In The Netherlands ~200.000 patients suffer from heart failure, and the 
number of patients increases with 10% every year. In general, the prognosis of patients 
with heart failure is poor; 70% of patients is still alive one year after diagnosis of heart 
failure and 35% is still alive five years after the diagnosis. Although medical care (of 
acute myocardial infarction) has considerably improved over the last decades, this 
paradoxically resulted in a higher prevalence of patients with heart failure3. This 
paradox is partly because the population is getter older4 but also because of the 
reduced number of people who die after myocardial infarction. Unfortunately, those 
people end up with heart failure, which decreases life expectancy and quality of live5;  
People with heart failure may experience breathlessness and coughing. Due to edema 
they experience swelling of the feet, ankles, legs or abdomen. People with heart failure 
may also experience heart palpitations. Therefore these patients would benefit 
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enormously from an improvement in cardiac function, which results in an 
improvement in symptoms. An improvement in cardiac function improves the 
prognosis of these patients6. 
 
Conventional pharmacological treatment of heart failure 
The more common forms of heart failure, those due to damage that has accumulated 
over time, cannot be cured, but they can be stabilized by lifestyle changes, medication 
or surgery. Lifestyle changes like quitting smoking, losing weight, avoiding alcohol and 
caffeine, eating a low-saturated-fat low-sodium diet, exercising and reducing stress 
can help to alleviate symptoms, slow the disease's progression and improve everyday 
life. Medication can also be used to slow the progression of heart failure. 
ACE inhibitors (angiotensin-converting-enzyme inhibitors) are now 
considered first-choice treatment and are the cornerstone of heart failure drug 
therapy7. ACE inhibitors limit the formation of angiotensin II. Angiotensin II causes 
small blood vessels to constrict, which raises blood pressure and places more stress on 
the heart. ACE inhibitors prevent cardiac hypertrophy8, prevent fibrosis and decrease 
afterload and preload. In stead of ACE inhibitors, Angiotensin II receptor blockers can 
be prescribed. Diuretics are prescribed for almost all patients who have volume 
overload in the body and swelling of the tissues. This helps to relieve the heart's 
workload, since there is less fluid and at lower preload to pump throughout the body. 
Digoxin increases the force of the heart's contractions. This relieves heart failure 
symptoms, especially when the patient is not responding to ACE inhibitors and 
diuretics. Beta-blockers are prescribed to most patients to reduce heart rate and lower 
blood pressure. They also inhibit ventricular remodeling and reduce the risk of 
arrhythmias and sudden death9. 
At this moment there is no sufficient treatment for patient with end-stage 
heart failure. Medical therapy can attenuate remodeling and improve survival but does 
not change the size of the scar. Drug treatment does not lead to sufficient recovery of 
left ventricular function. Unfortunately, angioplasty or bypass surgery does not 
reverse the damage in the myocardium after infarction. Transplantable donor hearts 
are scarce, and left ventricular assist devices can prolong patient lives only for several 
weeks or months. Therefore, there is an urgent demand for a new therapy to treat 
patients suffering from heart failure after a myocardial infarction. 
 
Stem cell therapy 
Several animals such as planarian platworms and amphibians have the ability to 
regrow missing body parts with speed and precision. This remarkable physiological 
process is called regeneration. Salamanders for example can regenerate lost body 
parts10, like a limb, by dedifferentiation of specialized cells into stem cells. 
Subsequently, these cells proliferate and will eventually differentiate into the 
specialized cells of the regenerated organ. This second process is similar to what 
happens in the blastula of embryos. Zebrafish are able to regenerate their heart 
completely.11 Humans have lost most of their regenerative capacity, except for wound 
healing and liver regeneration after partial hepatectomy. The human heart was always 
thought to be a terminally differentiated organ, however almost ten years ago it 
became clear that cardiomyocytes can divide12. It became clear that this even 
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happened after myocardial infarction13. The hope that patients who suffer from 
myocardial infarction can be treated with stem cells is based on this remarkable 
regeneration ability of animals14, on observations of bone marrow transplants in 
patients suffering from leukemia, and on the recently discovered plasticity of the 
human heart. The presence of donor bone marrow cells in the hearts of patients that 
underwent a bone marrow transplantation15 suggests that bone marrow might play a 
role in repairing the myocardium and vasculature. 
Experimental studies in rodents showed a great potential of stem cells in the 
regeneration of infarcted myocardium16. Injection of stem cell therapy after 
experimental myocardial infarction in rodents caused an improvement of left 
ventricular function and regeneration of the infarcted myocardium by newly formed 
myocytes and blood vessels17. In the last decade more than 100 experimental studies 
that have used stem cells to regenerate the myocardium after infarction have been 
published. Initially they all invariably demonstrated a positive effect on left ventricular 
function and infarct size after injection. Therefore, these positive results in 
experimental studies suggest that stem cell therapy could offer a therapy for patients 
suffering from myocardial infarction and may prevent the development of heart 
failure. 
To date several clinical trials have been completed18-27, which all used bone 
marrow or blood derived cells to treat patients after acute myocardial infarction. In 
these trials, there are differences in selection and in vitro processing of the bone 
marrow derived cells. There are also differences in inclusion criteria between the 
trials, differences in the timing of cell injection, follow-up time and choice of end-
points28-30. Although left ventricular function increases in most trials after stem cell 
therapy, this was not the case for all trials21-23. The BOOST-update26 showed that the 
initial benefit of mononuclear cell injection after acute myocardial infarction was lost 
over time compared to the controls. Therefore, the long-term efficacy of stem cell 
therapy needs to be determined. Furthermore, the mechanistic basis of the 
improvement observed in cardiac function in clinical trials is not explained in these 
studies.  
There are many questions that need to be answered before stem cell therapy 
can be applied as a standard treatment for patients31.  
 
Cell type 
It remains unclear which cell32, in which numbers, will lead to the optimal recovery of 
left ventricular function after myocardial infarction. A variety of cell types have been 
identified, each with distinct characteristics with varying potency to repair infarcted 
myocardium and with different advantages and disadvantages33. Bone marrow or 
blood is an easily available and safe cell source containing several side populations 
which have been used in previous studies, e.g. hematopoietic cells34, endothelial 
progenitor cells35, CD133+ (Cellular Differentiation nomenclature) cells18 and 
mesenchymal stems36. A potential disadvantage of bone marrow derived cells is that 
they are harvested from a diseased person. It has been demonstrated that bone 
marrow cells from patients suffering from heart failure have decreased proliferation, 
migration and differentiation capacity37. The major advantage of bone marrow or 
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blood derived cells is that they can be easily injected intracoronary and it is an 
autologous cell source28. 
Although the intramyocardial injection of skeletal myoblasts38 can lead to 
replacement of scar tissue by myotubes, these cells fail to electromechanically couple 
to resident myocytes in vivo35. In patients, this potentially induces arrhythmias39, and 
therefore, these cells are currently only implanted in patients with an internal 
defibrillator. 
The use of embryonic stems cells raises ethical difficulties, however these cells 
have a great potential to differentiate into cardiomyocytes and integrate structurally 
with recipient myocytes. However, there are concerns about the tumorigenicity of 
embryonic stem cells40. Therefore, embryonic stem cells are not yet ready to be tested 
in clinical trials. 
Recently, several populations of resident cardiac stem/progenitor cells have 
been identified41. More research need to be performed before it will become clear 
whether these cells can be easily isolated, expanded and injected in patients or 
activated in-situ to replace scar tissue. 
 
Timing and route of administration 
Timing of cell injection42 after infarction and the route of cell administration43 could 
influence the potential capacity of stem cells to regenerate the myocardium. Several 
modes of cell administration have been investigated, including intramyocardial, 
intravenous, transendocardial and epicardial as well as intracoronary injection43,44. 
The major advantage of intracoronary injection is the wide infusion of the cells in the 
infarct area. In contrast, intravenous injection is thought to cause less sufficient 
homing of the injected cells to the site of injury. This is in contrast to intramyocardial 
injection, where cells are only distributed in the injected tissue. However, it is not 
clear yet which injection method will lead to optimal recovery of left ventricular infarct 
size after myocardial infarction. 
It should be investigated whether the route of administration or the injection 
of certain cell types can cause micro infarctions, which has been demonstrated in 
dogs45.  
 
Mechanism of cardiac regeneration 
Although all initial preclinical stem cell studies showed a beneficial effect of stem cell 
therapy, to date, there also are several clinical and preclinical studies with neutral or 
even negative effects of stem cell therapy. Taken together all the reports on the effect 
of stem cells after myocardial infarction, these findings are sometimes confusing and 
contradicting46.  
So far, the mechanism of cardiac regeneration remains unclear. Even the 
regenerative capacity of, for example, zebrafish is not fully understood yet. Until the 
mechanism of regeneration of myocardium after infarction is understood in 
experimental models, further optimalised stem therapy cannot be applied yet to 
patients in routine clinical practice. 
 
Determination of the effects of stem cell therapy 
 12
Introduction 
To evaluate the effect and efficacy of stem cell therapy on the heart after infarction 
several imaging modalities can be used to assess left ventricular function and infarct 
size. In clinical trials, magnetic resonance imaging is predominantly performed to 
evaluate cardiac function before and after stem cell injection47. Cardiac volumes, 
myocardial mass, global function, regional function and infarct size can be measured 
non-invasive with magnetic resonance to evaluate the effect of stem cell therapy. 
Cell labeling is a method to track cells after injection and to investigate the fate 
of the injected cells. Tracking can be preformed directly in vivo using magnetic 
resonance imaging or single-photon emission computed tomography for example, but 
cells can also be tracked ex vivo using histology. Immunohistochemistry makes it 
possible to determine the phenotype of the injected cells. This will help understanding 
the mechanism of cardiac regeneration. 
 
Aim of the present thesis 
The aim of this thesis is to validate non-invasive imaging techniques for infarct size 
measurement, to assess safety and efficacy of several stem cell sources and to explore a 
method to track the cells in vivo. 
This thesis addresses the promising novel stem cell treatment for patients suffering 
from myocardial infarction using a large, more translational, animal model. Previous 
studies in rodents all induced a myocardial infarction by permanent ligation of a 
coronary artery, and therefore the route of administration of stem cells was limited to 
intramyocardial16 or intravenous48 injection. However in patients, the standard 
therapy for myocardial infarction as described in the guidelines is reperfusion therapy, 
preferably by percutaneous coronary intervention. Furthermore, in most clinical trials, 
bone marrow or blood derived stem cells were injected intracoronary in patients with 
acute myocardial infarction. To evaluate the potential of stem cell therapy, we 
investigated the effect of intracoronary stem cell injection in a porcine pre-clinical 
model of myocardial infarction followed by reperfusion which closely mimics clinical 
settings.    
 Chapters two and three describe the imaging techniques used to assess left 
ventricular function and infarct size in our model. In chapter two infarct size 
measurement by multislice computed tomography is compared with histology. In 
chapter three infarct size is assessed by both computed tomography and magnetic 
resonance imaging. 
 In chapters four to six the effects of stem cell therapy on left ventricular 
function and infarct size after myocardial infarction are described. To address these 
effects, we used magnetic resonance imaging to study several different stem cells. The 
initial experiences with human umbilical cord blood derived cells in animal models is 
reviewed in chapter four, while the effects of human umbilical cord blood derived 
unrestricted somatic stem cells on the porcine left ventricular function after 
myocardial infarction has been described in chapter five. In chapter six, the effect of 
autologous unselected bone marrow is compared with mononuclear cells isolated from 
the bone marrow. 
In chapters five and six we injected cells intracoronary at a normal arterial flow 
rate, while clinical trials used the method of intermittent balloon occlusion. Therefore 
we investigated in chapter seven whether there are differences in cell engraftment 
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after cell injection during normal/uninterrupted coronary blood flow and after 
injection during intermittent balloon occlusion.  
Since we observed in chapter five that cultured umbilical cord blood derived 
cells caused micro infarctions after intracoronary injection, we hypothesized that this 
could also occur after the injection of cultured bone marrow derived cells. In chapter 
eight the differences between injections of cultured bone marrow derived 
mononuclear cells and freshly isolated mononuclear cells are addressed.  
To investigate the fate of injected cells in vivo, injected cells need to be 
recognized after injection. Autologous cells are not easy to track in vivo. In chapter 
nine iron-oxide labeling is evaluated as a possible marker for stem cell tracking after 
injection. 
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Assessment of infarction with CT 
Abstract 
 
Objective The purpose of this study was to evaluate the utility of delayed enhancement 
64-MDCT in the assessment of myocardial infarct size in a porcine model of acute 
reperfused myocardial infarction. CT can be used for noninvasive assessment of 
coronary artery stenosis, but to our knowledge, evaluation of myocardial viability in 
the subacute phase of acute myocardial infarction has not been validated. We 
performed delayed enhancement imaging on six domestic swine 5 days after 
reperfused acute myocardial infarction and assessed the relation between delayed 
enhancement patterns in vivo and the extent of viable and nonviable myocardium at 
postmortem histochemical analysis.  
 
Conclusion Delayed enhancement imaging with 64-MDCT can be used for accurate 
assessment of the size of reperfused acute myocardial infarcts.  
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Introduction 
 
MDCT is used for the evaluation of coronary artery disease and has high diagnostic 
accuracy in the detection of coronary artery stenosis1,2. The diagnostic value of MDCT 
for assessment of myocardial viability in the subacute phase of acute myocardial 
infarction is unclear. Studies3,4 have shown that MDCT during the first pass after 
administration of an iodinated contrast agent results in low tissue contrast between 
infarcted and uninfarcted myocardium and that total infarct size appears to be 
underestimated. A delayed enhancement imaging protocol as used in MRI may be an 
alternative approach. Excellent tissue contrast with MRI is obtained 10–30 minutes 
after administration of gadolinium derivatives, because this type of contrast agent 
accumulates in the infarcted tissue. The pharmacokinetic behavior of gadolinium 
chelates is somewhat similar to that of iodinated contrast agents5. We performed 
delayed enhancement MDCT in a porcine model of reperfused acute myocardial 
infarction to investigate whether reperfused infarct size can be assessed accurately 
with delayed enhancement MDCT.  
Materials and Methods 
 
Animal Model  
Six Yorkshire-Landrace pigs (age, 2–3 months; weight, 22 kg) were subjected to 
coronary angiography followed by balloon occlusion of the left circumflex coronary 
artery. Reperfusion was obtained by deflation of the balloon after 2 hours of ischemia. 
The study complied with the regulations of the animal care committee of the Erasmus 
Medical Center and the “Guide for the Care and Use of Laboratory Animals” (National 
Institutes of Health, 1996). Animals were sedated (ketamine 20 mg/kg 
intramuscularly and midazolam 1 mg/kg intramuscularly), anesthetized (thiopental, 
12 mg/kg IV), intubated, and mechanically ventilated (mixture of oxygen and 
nitrogen, 1:2). Anesthesia was maintained with fentanyl (12.5 µg/kg/h).  
CT  
Five days after induction of myocardial infarction, all swine were anesthetized as 
described earlier and subjected to MDCT. Mean heart rate decreased from 
approximately 80 to 45 ± 9 beats per minute (BPM) after administration of 
zatebradine (10 mg/kg IV). A 64-MDCT scanner (Sensation 64, Siemens Medical 
Solutions) was used for imaging with the following characteristics: number of detector 
rows, 32 × 2 (oversampling in the z-axis obtained with flying focal spot); number of 
slices per rotation, 64; individual detector width, 0.6 mm; gantry rotation time, 330 
milliseconds; effective temporal resolution, 165 milliseconds. Delayed enhancement 
imaging was performed 15 minutes after administration of 80 mL of iodinated 
contrast agent (iomeprol 400 mg I/mL, Iomeron, Bracco) through an ear vein. The 
following scan parameters were used: effective tube current, 900 mAs at kV 120; feed 
per rotation, 3.84 mm; scan direction, craniocaudal. The estimated radiation dose if 
used for a human protocol would have been 15 mSv for men and 21 mSv for women. 
Delayed enhancement MDCT data sets were reconstructed at –300, –350, and –400 
milliseconds before the next R wave (end-diastolic phase of the cardiac cycle). From 
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the data set with optimal image quality, images with a slice thickness of 1 mm and an 
increment of 0.5 mm were reconstructed in the short-axis view with a dedicated 
software platform with multiplanar capabilities (Leonardo, Siemens).  
Data Analysis  
One day after MDCT, all pigs were sacrificed and the hearts excised. The myocardium 
of the left ventricle was cut in 8-mm consecutive slices in the short-axis view with a 
commercially available meat slicer. For viability staining, the slices were embedded in 
a solution of 1% triphenyltetrazolium chloride (TTC) and 0.2 mol/L Sörensen’s buffer 
(pH, 7.4) at 37°C for 15 minutes and then fixed in 4% formalin. The slices were 
photographed with a digital camera. The digitalized TTC-stained slices were loaded in 
a separate workstation with a commercially available analysis package (SigmaScan Pro 
5.0, Systat). TTC-negative borders and endocardial and epicardial borders of the left 
ventricle were traced manually in all consecutive slices. Infarct size was defined as 
TTC-negative area as a percentage of total left ventricular slice area.  
Reconstructed MDCT images were exported and transferred to a separate 
workstation with dedicated software (Cine Tool, GE Healthcare). The region with 
delayed enhancement was selected manually on these images. Infarct size per slice 
was calculated by dividing the delayed enhanced area by the total slice area. CT 
attenuation values were measured by drawing three 10-mm2 regions of interest in 
delayed enhanced myocardium, remote myocardium, and the left ventricular cavity in 
a short-axis slice located at the center of the infarction of each pig3.  
 
Statistical Analysis  
Data were presented as mean ± SD. Univariate linear regression analysis and Bland-
Altman analysis were used to evaluate the relation between infarct size measured with 
MDCT and infarct size measured with postmortem histochemical analysis. One-way 
analysis of variance with repeated measures was used for the comparison of CT 
attenuation values of delayed enhanced myocardium, remote myocardium, and the 
left ventricular cavity. Posthoc Bonferroni correction was applied to adjust for 
multiple comparisons. Significance was accepted at p ≤ 0.05 (two-tailed).  
 
 
Results 
 
All MDCT data sets were of good image quality. Delayed enhancement observed in the 
lateral wall of the left ventricle corresponded to the perfusion territory of the 
circumflex coronary artery (Figs. 1 and 2). No delayed enhancement was seen in 
remote myocardium. Four of the 42 available histochemical slices had to be excluded 
because postmortem shrinkage made measurement of infarct area and slice area 
impossible. TTC- negative areas (infarcted myocardium) were found in the lateral wall 
of the left ventricle but not in remote myocardium (Figs. 1 and 2).  
Mean infarct size was 28% ± 13% on MDCT images and 26% ± 12% on histochemical 
images. Infarct size measured with MDCT correlated well with infarct size measured 
on histochemical images (R2=0.92; p <0.001) (Fig. 3). The mean MDCT value of 
delayed enhanced myocardium (141 ± 10 H) was significantly different from that of 
remote myocardium (71 ± 8 H; p < 0.001) and from that of the left ventricular cavity 
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(115 ± 8 H; p < 0.001). The relative difference in MDCT value between infarcted and 
uninfarcted myocardium was 206% ± 14%. 
 
 
A             B 
Fig. 1 Pig with subendocardial myocardial infarction. A, Photograph of postmortem histochemical 
specimen in midventricular short-axis view shows infarct (arrows). B, Delayed enhancement MDCT scan 
in midventricular short-axis view shows infarct (arrows). 
 
 
A              B 
Fig. 2 Pig with transmural myocardial infarction. A, Photograph of histochemical specimen in short-axis 
view shows infarct (arrows). B, Delayed enhancement MDCT scan of specimen shows infarct (arrows).  
Discussion 
 
MDCT technology has developed rapidly with a marked increase in temporal and 
spatial resolution. Noninvasive evaluation of coronary artery disease is feasible, and 
several studies have shown good diagnostic accuracy in the detection of coronary 
artery stenosis. Evaluation of myocardial viability in the subacute phase of acute 
myocardial infarction has been studied with MDCT, but limited data are available. For 
example, Hoffmann et al.3 performed MDCT coronary angiography within 5 hours 
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Fig. 3—Reliability of MDCT versus histochemical analysis in assessment of acute 
reperfused myocardial infarct size per slice. A, Graph shows results of linear regression analysis. B, 
Graph shows results of Bland-Altman analysis. 
 
of acute nonreperfused myocardial infarction in swine and found good correlation 
between the size of perfusion defects and the size of infarcts estimated at postmortem 
histochemical analysis. Mahnken et al.6 performed 16-MDCT coronary angiography 
followed by delayed enhancement CT and MRI in patients within 14 days of 
reperfused acute myocardial infarction. Infarct size measured on delayed 
enhancement CT and delayed enhancement MRI was comparable, but infarct size 
measured on perfusion images remained underestimated.  
In this study, we used an experimental model of reperfused acute myocardial 
infarction because early aggressive reperfusion is currently the preferred treatment in 
the clinical setting of acute myocardial infarction. Delayed enhancement imaging was 
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performed because the contrast agents used for MDCT (iodinated contrast material) 
and MRI (gadolinium derivatives) accumulate in infarcted myocardium 10–30 min-
utes after IV administration while they are being washed out of remote myocardium7,8. 
We did not perform perfusion imaging because MRI studies of reperfused myocardial 
infarction have shown that total infarct size remains underestimated with perfusion 
imaging. During the first pass of a contrast agent, infarcted myocardium with an intact 
microvasculature becomes normally enhanced while infarcted myocardium with 
microvascular obstruction appears as a perfusion defect9. We found that infarct size 
can be assessed accurately with delayed enhancement 64-MDCT if imaging is 
performed 5 days after reperfused myocardial infarction.  
A well-known concern about MDCT is the use of iodinated contrast agents and 
radiation exposure to the patient. Our results encourage further research into 
optimization of protocols that involve use of less radiation and less iodinated contrast 
material and into optimal timing of de ayed enhancement imaging after contrast 
administration. Furthermore, image quality is heart rate dependent, and images may 
be impaired at heart rates greater than 70 BPM10.  
Measurement of infarct size in patients with acute myocardial infarction is 
clinically relevant because infarct size is predictive of left of myocardial viability in 
reperfused acute myocarventricular function and geometric configuration and, hence, 
long-term clinical outcome11,12. Information on infarct size obtained with MDCT would 
enhance the diagnostic armamentarium of physicians who lack access to RM. 
Myocardial magnetic resonance imaging cardiac MRI or encounter patients who have 
contraindications to MRI. 
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Abstract 
 
Objectives We evaluated the accuracy of in vivo delayed-enhancement multislice 
computed tomography (DE-MSCT) and delayed-enhancement magnetic resonance 
imaging (DE-MRI) for the assessment of myocardial infarct size using postmortem 
triphenyltetrazolium chloride (TTC) pathology as standard of reference.  
 
Background The diagnostic value of DE-MSCT for the assessment of acute reperfused 
myocardial infarction is currently unclear. 
 
Methods In 10 domestic pigs (25 to 30 kg), the circumflex coronary artery was 
balloon-occluded for 2 h followed by reperfusion. After 5 days (3 to 7 days), DE-MRI 
(1.5-T) was performed 15 min after administration of 0.2 mmol/kg gadolinium-DTPA 
using an inversion recovery gradient echo technique. On the same day, DE-MSCT (64-
slice) was performed 15 min after administration of 1 gI/kg of iodinated contrast 
material. One day after imaging, hearts were excised, sectioned in 8 mm short-axis 
slices, and stained with TTC. Infarct size was defined as the hyperenhanced area on 
DE-MSCT and DE-MRI images and the TTC-negative area on TTC pathology slices. 
Infarct size was expressed as percentage of total slice area. 
 
Results Infarct size determined by DE-MSCT and DE-MRI showed a good correlation 
with infarct size assessed with TTC pathology (R2=0.96 [p=0.001] and R2=0.93 
[p=0.001], respectively). The correlation between DE-MSCT and DE-MRI was also 
good (R2=0.96; p=0.001). The relative difference in CT attenuation value of infarcted 
myocardium compared to remote myocardium was 191±18%. The relative MR signal 
intensity between infarcted myocardium and remote myocardium was 554±156%. 
 
Conclusions We demonstrated that DE-MSCT can assess acute reperfused myocardial 
infarction in good agreement with in vivo DE-MRI and TTC pathology. 
 
Abbreviations and Acronyms 
CT =   computerized tomography  
DE-MRI = delayed-enhancement magnetic resonance imaging  
DE-MSCT = delayed-enhancement multislice computed tomography  
HU =  Hounsfield units  
TTC=  triphenyltetrazolium chloride  
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Introduction 
 
Acute myocardial infarct size is a predictor of long-term left ventricular function and 
geometry and clinical outcome in patients who have suffered acute myocardial 
infarction1,2. Delayed-enhancement magnetic resonance imaging (DEMRI) is a well 
established noninvasive imaging modality that allows assessment of myocardial 
infarct size3–5. In recent years, multislice computed tomography (MSCT) technology 
has made great strides, and noninvasive assessment of coronary artery stenosis is now 
feasible with high diagnostic accuracy using a 64-slice scanner6,7. Delayed-
enhancement multislice computed tomography (DEMSCT) has been proposed as an 
alternative noninvasive imaging modality for the detection of myocardial infarction. 
However, different imaging protocols have been proposed at different time points 
after myocardial infarction, and the diagnostic accuracy is currently unclear8–11. We 
performed DE-MSCT and DE-MRI in a porcine model of reperfused acute myocardial 
infarction at a mean of five days after infarction. We evaluated the accuracy of in vivo 
DE-MSCT and DE-MRI for the assessment of acute reperfused myocardial infarct size 
and used postmortem viability staining with triphenyltetrazolium chloride (TTC) as 
standard of reference.  
 
Methods 
 
Animal model 
Fourteen Yorkshire-landrace pigs (2 to 3 months old, 25 to 30 kg) were sedated 
(ketamine 20 mg/kg intramuscular and midazolam 1 mg/kg intramuscular), 
anesthetized (thiopental, 12 mg/kg intravenously), intubated, and mechanically 
ventilated (mixture of oxygen and nitrogen 1:2). Anesthesia was maintained with 
fentanyl (12.5 µg/kg/h). All pigs then received a sheath in a carotid artery to allow 
coronary X-ray angiography. Under fluoroscopy guidance, balloon occlusion of the left 
circumflex coronary artery was performed. In 2 pigs, the balloon was deflated after 15 
min of occlusion to produce severely ischemic but reversible injured (stunned) 
myocardium. In 12 pigs, the balloon was deflated after 2 h of occlusion to allow 
reperfusion of the infarcted area. Reperfusion was proven by coronary angiography. 
Of the animals who underwent 2 h of occlusion, one pig died after 1 day and one pig 
died after 3 days after balloon occlusion. The study complied with the regulations of 
the animal care committee of our hospital and the National Institutes of Health 
publication “Guide for the Care and Use of Laboratory Animals” (1996).  
All pigs were anesthetized as described above before imaging. First, DE-MRI 
was performed, and 93±23 min later DE-MSCT imaging. The two pigs that underwent 
15 min of balloon occlusion underwent imaging at 3 and 4 days, respectively, after 
induction of ischemia. Of the 10 remaining pigs that underwent the 2-h occlusion 
protocol, 2 pigs were imaged at 3 days, 6 at 5 days, and 2 at 7 days after reperfusion. 
One day after the DE-MSCT and DE-MRI imaging session, all animals were 
euthanized and their hearts excised. The ex vivo hearts were stiffened using alginate 
impression material (Cavex Holland, Haarlem, the Netherlands). The myocardium of 
the left ventricle was then sectioned in 8 mm consecutive slices in short-axis view 
perpendicular to the long axis of the left ventricle using a commercially available 
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meatslicer. To obtain a viability staining, the slices were embedded in a solution of 1% 
triphenyltetrazolium chloride (TTC) and 0.2 mol/l Sorensen’s buffer (pH 7.4) at 37°C 
for 15 min, followed by fixation in 4% formalin. Slices that showed a TTC-negative area 
were photographed digitally after 24 h of exposure to formalin. Exposure to formalin 
allows delineation between necrotic but hemorrhagic myocardium (which has a red 
appearance due to the presence of blood) and viable tissue (which stains red owing to 
the conversion of TTC to the bright red formazan stain). By exposing the TTC-stained 
tissue to formalin, the hemorrhagic necrotic areas acquire a dark brown color, whereas 
the red formazan precipitate remains bright red (Fig. 1). Unfortunately, a limitation of 
this approach was the asymmetric shrinkage (causing the slices to bend) in 9 out of a 
total of 67 slices (in 10 animals), hampering the accurate assessment of infarct size in 
these slices, which were excluded from analysis for this reason.  
 
DE-MSCT 
A 64-slice clinical CT scanner was used for imaging (Sensation 64; Siemens, 
Forchheim, Germany) with the following characteristics: number of detector rows 
32x2 (oversampling in the z-axis obtained with flying focal spot12); individual detector 
width 0.6 mm; gantry rotation time 330 ms; effective temporal resolution 165 ms. The 
delayed-enhancement protocol was performed 15 min after administration of 1 gI/kg 
of iodinated contrast agent through an ear vein at an injection speed of 1.5 ml/s (400 
mgI/ml Iomeprol; Iomeron, Bracco, Italy). The following scan parameters were used: 
tube voltage 120 kV; tube current 900 mA; table feed per rotation 3.84 mm; scan 
direction craniocaudal and retrospective electrocardiographic gating. Voxel size at 
acquisition was 0.3x0.3x0.4 mm. The estimated radiation dose if applied in humans 
was calculated with dedicated software as 15/21 mSv for male/ female (WinDose; 
Institute of Medical Physics, Erlangen, Germany). Mean heart rate decreased to 51±9 
beats/min after administration of zatebradine (10 mg/kg intravenously). An 
instrumented breath hold was applied to minimize the influence of respiratory motion 
on data collection. The DE-MSCT datasets were reconstructed at 300 ms, 350 ms, and 
400 ms before the next R-wave (enddiastolic phase of the cardiac cycle). From the 
dataset with optimal image quality, axial slices with a slice thickness of 1 mm and an 
increment of 0.5 mm were reconstructed using a field of view of 150x50 mm, a 512 
mm2
 
reconstruction matrix, and a medium smooth convolution filter (B30f). The 
MSCT short-axis slices with a slice thickness of 1 mm were then reconstructed 
perpendicular to the long axis of a double-oblique true four-chamber view using a 
dedicated software platform with multiplanar capabilities (Leonardo; Siemens).  
 
DE-MRI 
A clinical 1.5-T MRI scanner with a dedicated cardiac four-element phased-array 
receiver coil was used for imaging (Signa CV/i; GE Medical Systems, Milwaukee, 
Wisconsin). Repeated instrumented breath-holds and gating to the electrocardiogram 
were applied to minimize the influence of cardiac and respiratory motion on data 
collection. No medication was administered to control heart rate. Cine-MRI was 
performed with a steady-state free-precession technique (Fiesta; Medical Systems) 
with the following imaging parameters: 24 temporal phases per slice, voxel size 
1.8x1.5x8 mm; repetition time 3.4 ms; time to echo 1.4 ms; flip angle 45° bandwidth 
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83 kHz; number of averages 0.75. To cover the entire left ventricle, six to eight 
consecutive slices of 8 mm were planned in short-axis view perpendicular to the long 
axis of a double-oblique true four-chamber view.  
Myocardial distribution of delayed enhancement was studied 15 min after 
administration of Gadolinium-DTPA (0.2 mmol/kg; Magnevist, Schering, Germany). 
A two-dimensional T1-weighted inversion-recovery segmented fast gradient-echo 
sequence with the following imaging parameters was used: voxel size 1.1x1.5x8mm; 
repetition time 7.3 ms; time to echo 1.6 ms; flip angle 20°; inversion pulse 180°; 
number of averages 1; bandwidth 17.9 kHz; inversion time 180 to 300 ms; data 
acquisition every second R-R interval. The trigger delay was adjusted per pig to 
acquire data in mid-to end-diastole, and the inversion time was adjusted per pig to 
null the signal of remote myocardium. Slice locations for delayed-enhancement im-
aging were copied from slice locations of short-axis cine-imaging.  
 
Data analysis 
The DE-MSCT, DE-MRI, and TTC pathology images were coregistered using 
anatomical landmarks like the insertion of the right ventricle to the septum and the 
presence of papillary muscles. Infarct size per slice was calculated by dividing the 
infarcted area by the total slice area of left ventricular myocardium. The digitalized 
TTC pathology slices were loaded in a separate workstation with a commercially 
available analysis package (SigmaScan Pro 5.0). The TTC negative area (including the 
dark-brown subendocardial area) was considered to be the infarcted area and was 
segmented manually. Reconstructed DE-MSCT images and DE-MRI images were 
exported and transferred to a separate workstation with dedicated software (Cine Tool 
3.4; GE Medical Systems). Image quality was evaluated on a per-slice basis and 
classified as good (defined as the absence of any image-degrading artifacts related to 
motion or miss-triggering), adequate (presence of image-degrading artifacts but 
evaluation possible), or poor (presence of image-degrading artifacts but evaluation 
possible with moderate confidence). The region with delayed hyper-enhancement was 
segmented manually by two different observers (T.B. and A.M.) blinded to the results 
of the other imaging modality and TTC pathology. Regional wall thickening was 
assessed on cine-MRI images at the core of the infarction and in remote noninfarcted 
myocardium of the septum using dedicated software based on the centerline method 
(CAAS MRV 2.1, Pie Medical Imaging, Maastricht, the Netherlands). CT attenuation 
values (expressed in Hounsfield Units [HU]) were measured using the scanner 
software by drawing three 10-mm2
 
regions of interest in delayed enhanced 
myocardium, remote myocardium and the left ventricular cavity in a short axis slice 
located at the center of the infarction of each pig11. Noise was considered to be the 
standard deviation of the CT value in a region of interest of 25 mm2
 
placed in the 
descending thoracic aorta. The MRI signal intensity values (expressed in arbitrary 
units [AU]) were measured using the scanner software by drawing 30 mm2 regions of 
interest in delayed enhanced and remote myocardium13. Signal intensity of the left 
ventricular blood pool was measured by drawing a 100 mm2
 
region of interest in the 
left ventricular cavity. Noise was considered to be the standard deviation of the signal 
measured in a region of interest 300 mm2
 
placed in the imaged air outside of the pig.  
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Statistical analysis 
All data are presented as mean±standard deviation. The relation between infarct size 
assessed with DE-MSCT, DE-MRI, and TTC pathology was evaluated with univariate 
linear regression analysis. Agreement between DE-MSCT, DE-MRI, and TTC 
pathology for the assessment of infarct size and intra-and interobserver variability was 
determined with Bland-Altman analysis. Differences in regional wall thickening were 
tested with an unpaired ttest. Differences in CT attenuation values and MR signal 
intensity values between infarcted myocardium, remote myocardium, and left 
ventricular blood pool were tested with one-way analysis of variance followed by post 
hoc Bonferroni correction to adjust for multiple comparisons. 
 
Results 
 
The two pigs that underwent 15 min of balloon occlusion of the circumflex coronary 
artery showed hypokinesia of the lateral wall on echocardiography performed 20 min 
after reperfusion, indicating the presence of stunned myocardium. The DE-MSCT and 
DE-MRI imaging demonstrated no regions with delayed enhancement. The TTC 
staining confirmed that there was no infarcted myocardium. In 10 pigs that underwent 
2-h balloon occlusion of the circumflex coronary artery, acute reperfused myocardial 
infarction was accurately detected by both DE-MSCT and DE-MRI (Figs. 1 and 2). The 
DE-MSCT image quality was classified as good in 83% (48 of 58), moderate in 10% (6 
of 58), and poor in 7% (4 of 58) of slices. The DE-MR image quality was classified as 
good in 75% (43 of 58), moderate in 17% (10 of 58), and poor in 8% (5 of 58) of slices. 
No delayed enhancement was seen in myocardium outside the perfusion territory of 
the circumflex coronary artery. Mean infarct size was 21±15% on DE-MSCT images, 
22±16% on DE-MR images, and 20±15% on TTC pathology images. Infarct size 
assessed with DEMSCT correlated well with infarct size measured on TTC pathology 
slices (R2=0.96; p=0.001). Also, infarct size assessed with DE-MRI correlated well 
with infarct size measured on TTC pathology slices ((R2=0.93; p=0.001). Accordingly, 
infarct size assessed with DE-MSCT correlated well with infarct size assessed with DE-
MRI ((R2=0.96; p=0.001) (Fig. 3A). Bland-Altman analyses demonstrated a good 
agreement for the assessment of infarct size between DE-MSCT, DE-MRI, and TTC 
pathology (Fig. 3B). The intraobserver variability for the assessment of infarct size was 
1.0±3.9% for DE- MSCT and 0.5±4.6% for DE-MRI. The interobserver variability for 
the assessment of infarct size was 2.1±5.6% for DE-MSCT and 3.0±5.9% for DE-MRI. 
Regional wall thickening was significantly decreased in infarcted myocardium of the 
lateral wall compared with remote noninfarcted myocardium of the septum (0±14% 
vs. 50± 14%; p=0.001) (Fig. 4).  
Mean CT attenuation value of delayed-enhanced myocardium was significantly 
different from CT attenuation value of remote myocardium (126±20 HU vs. 66±6HU; 
p=0.001; three pair-wise comparisons) (Fig. 5). The relative difference in CT 
attenuation value between delayed-enhanced and remote myocardium was 191±18%. 
Noise measured in the descending aorta was 17±3 HU. Mean MR signal intensity value 
of delayed-enhanced myocardium was significantly higher than MR signal intensity of 
remote myocardium (154±37 AU vs. 28±6 AU; p=0.001; three pairwise comparisons) 
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Figure 1 Acute reperfused myocardial infarction can be assessed accurately with delayed-enhancement 
multislice computed tomography (DE-MSCT) and delayed-enhancement magnetic resonance imaging 
(DE-MRI) compared with postmortem triphenyltetrazolium chloride (TTC) pathology. The left ventricle 
is shown from base (Slice 1) to apex (Slice 6). The MSCT images represent 1-mm slices compared with the 
photographed TTC pathology slices and the MRI slices of 8 mm. 
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Figure 2 In this pig with subendocardial infarction, the transmural differentiation of viable and 
nonviable myocardium is demonstrated with DE-MSCT in short-axis view (B) and long-axis view (C) 
with TTC pathology as standard of reference (A). 
 
 (Fig. 5). Relative MR signal intensity value of delayed-enhanced myocardium 
compared with remote myocardium was 554±156%. Noise measured in the air outside 
the pig was 6±1 AU.  
 
Discussion 
 
Our results demonstrate that DE-MSCT can assess acute reperfused myocardial 
infarction in good agreement with in vivo DE-MRI and postmortem TTC pathology.  
 
Delayed-enhancementimaging 
Delayed-enhancement imaging is feasible with MSCT and MRI because both iodinated 
contrast agents and gadolinium chelates passively diffuse into the increased 
extracellular matrix of infarcted myocardium14. Higgins et al.15 demonstrated elevated 
concentrations of iodinated contrast material in infarcted tissue compared with 
uninfarcted tissue if assessed more than 5 min after administration of these contrast 
materials. Rehwald et al.16 showed significantly higher concentrations of gadolinium 
chelates in infarcted myocardium compared with remote myocardium after a delay of 
10 min. Because accumulation of contrast agents in necrotic myocardium is a passive 
process, the timing between administration of contrast agents and imaging may be 
crucial to accurately assess infarct size. Amado et al.17 performed DE-MRI between 6 
and 30 min after administration of gadolinium chelates and observed no difference in 
measured infarct size. The optimal time delay for performing DEMSCT after 
administration of iodinated contrast agents remains to be determined, because no 
data are available for DE-MSCT in infarctions more than 2 days old. The 
pharmacokinetic behavior of gadolinium chelates and iodinated contrast agents is 
relatively similar, but differences in molecule size may influence the rate of diffusion 
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Figure 3 (A) The relation between infarct size assessed with DE-MSCT, DE-MRI, and postmortem TTC 
pathology. (B) Bland-Altman analyses show the excellent agreement between infarct size assessed with 
DE-MSCT, DE-MRI, and postmortem TTC pathology. Abbreviations as in Fig. 1.  
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Figure 4 Regional wall thickening was significantly reduced in infarcted compared with noninfarcted 
myocardium. 
 
 
Figure 5 Mean computerized tomography (CT) attenuation value for infarcted myocardium is 
significantly higher compared with noninfarcted myocardium. Mean magnetic resonance (MR) signal 
intensity value of infarcted myocardium is significantly higher compared with noninfarcted myocardium. 
*p=0.001 compared with infarcted myocardium. †p=0.001 compared with left ventricular (LV) blood 
pool.  
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Figure 6 DE-MSCT provides higher spatial resolution than DE-MRI. Image A represents an 8-mm-thick 
DE-MRI image, and image B represents the similar slice reconstructed from eight different 1-mm-thick 
DE-MSCT images. Images on the right represent the eight reconstructed 1-mm-thick slices that together 
form image B. Abbreviations as in Fig. 1.  
  
in infarcted myocardium18. 
 
DE-MSCT 
Delayed-enhancement CT for the assessment of myocardial infarction was performed 
as early as the late 1970s, and these initial results were encouraging19. However, 
practical use of this technique was hampered by insufficient image quality mainly 
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caused by cardiac motion. Computerized tomography technology has developed 
rapidly during the last decade, and with the introduction of spiral and later multislice 
spiral CT a marked increase in temporal and spatial resolution was obtained. Three 
recent experimental studies demonstrated the excellent diagnostic accuracy of 4-, 16-, 
and 32-slice CT for the assessment of nonreperfused and reperfused myocardial 
infarction if performed within 5 h after induction of infarction10,11,20. However, infarct 
morphology may change after myocardial infarction with early infarct expansion (~2 
days) and late infarct shrinkage (~10 days)5,21, and the ability of DE-MSCT to assess 
infarctions more than 5 h old is currently unknown. To assess infarct size between 2 
and 7 days after infarction is clinically relevant, because infarct size predicts long-term 
left ventricular remodeling and clinical outcome1,22–24. In the current study, we 
demonstrated that DE 64-slice CT can assess infarct size between 3 and 7 days after 
infarction and can differentiate between necrotic myocardium and stunned 
myocardium with good correlation with in vivo DE-MRI and ex vivo TTC pathology. 
More studies are needed to demonstrate if DE-MSCT can also show myocardial 
infarction or scar at a longer time of follow-up after myocardial infarction.  
An advantage of MSCT is that it offers high spatial resolution, allowing 
reconstruction of thin slices and thereby reducing possible partial volume artifacts. 
High-resolution DE-MSCT imaging also allowed the transmural differentiation of 
viable and nonviable myocardium. A major disadvantage of MSCT is the limited soft 
tissue contrast that is obtained. Tissue contrast is related to the radiation dose that is 
applied and the amount of iodinated contrast material administered. For DE-MSCT 
imaging, we used the radiation dose that is used for MSCT coronary angiography 
(15/21 mSv for men/women). We administered 1 gI/kg iodine contrast to the pigs, 
equivalent to approximately 200 ml iodine contrast to a patient of 70 kg, which is 
considered a normal dose of contrast during a conventional angiography procedure25. 
Technical developments are desirable that reduce radiation exposure and limit the 
amount of iodinated contrast material needed. Recent developments include tube-
current modulation which reduces radiation exposure by nearly one-half by applying 
radiation only in the mid-to end-diastolic phase of the cardiac cycle26.  
An advantage of MSCT is that it offers high spatial resolution, allowing 
reconstruction of thin slices and thereby reducing possible partial volume artifacts. 
High-resolution DE-MSCT imaging also allowed the transmural differentiation of 
viable and nonviable myocardium. A major disadvantage of MSCT is the limited soft 
tissue contrast that is obtained. Tissue contrast is related to the radiation dose that is 
applied and the amount of iodinated contrast material administered. For DE-MSCT 
imaging, we used the radiation dose that is used for MSCT coronary angiography 
(15/21 mSv for men/women). We administered 1 gI/kg iodine contrast to the pigs, 
equivalent to approximately 200 ml iodine contrast to a patient of 70 kg, which is 
considered a normal dose of contrast during a conventional angiography procedure 
(25). Technical developments are desirable that reduce radiation exposure and limit 
the amount of iodinated contrast material needed. Recent developments include tube-
current modulation which reduces radiation exposure by nearly one-half by applying 
radiation only in the mid-to end-diastolic phase of the cardiac cycle26.  
DE-MRI 
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Delayed-enhancement MRI is an established noninvasive imaging modality that can 
assess reperfused and nonreperfused myocardial infarction4. It is safe and patient 
friendly and can be repeated multiple times to evaluate therapy without causing harm 
to the patient. No heart rate control is necessary. Excellent soft tissue contrast is 
obtained with gadolinium chelates that have T1 shortening characteristics. Further 
improvement in tissue contrast is obtained by applying a nonselective inversion pulse 
before data acquisition, allowing suppression of signal of remote myocardium27. We 
observed a relative signal intensity between hyperenhanced and remote myocardium 
of 554±156%. A disadvantage of MRI is the limited through-plane resolution, resulting 
in a slice thickness of 4 to 8 mm (Fig. 6). In the present study, differences in infarct 
size between postmortem TTC pathology, DE-MSCT, and DE-MRI may have been 
caused by dissimilarity in slice thickness offered by these different modalities. The DE-
MSCT allowed reconstruction of a slice thickness of 1 mm, whereas DE-MRI was 
performed with a slice thickness of 8 mm, and TTC pathology, the standard of 
reference, was analyzed on a two-dimensional digital photograph. The accuracy and 
reproducibility of infarct size measurements with DE-MSCT and DE-MRI may further 
improve by using a semiautomated quantification software17.  
Conclusions 
 
Delayed-enhancement MRI is a well established noninvasive imaging modality that 
allows assessment of myocardial infarct size and has been shown to provide 
prognostic information in patients who have suffered acute myocardial infarction. We 
demonstrated that DE-MSCT can assess acute reperfused myocardial infarction in 
good agreement with in vivo DE-MRI and postmortem TTC pathology. Ongoing 
technical improvements of the CT scanner have resulted in high diagnostic 
performance to detect significant coronary stenosis in selected groups of patients 
without arrhythmia and a heart rate below 70 beats/min6,7. Together with the 
assessment of infarct size, this new CT technology may emerge as a clinically valuable 
tool to comprehensively evaluate post-infarction patients. 
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Abstract 
 
Umbilical cord blood (UCB) cells may offer a promising, of the shelf, therapy for the 
treatment of myocardial infarction. In this review the current use of UCB as an 
alternative to bone marrow to obtain cells for transplantation purposes is described. 
In addition, preclinical studies using umbilical cord blood derived cells for cardiac 
regeneration are discussed including our own experience in a porcine model of 
reperfused myocardial infarction. 
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Introduction 
 
Myocardial infarction (MI) is a major cause of heart failure and thus forms one of the 
main targets for cardiac regeneration by cell transplantation. The treatment of MI 
with stem cell therapy seems promising; however the cellular source with the highest 
potential for cardiac regeneration remains unclear. To optimally treat MI patients with 
stem cell therapy, a widely available source of stem cells would be of much use1. Many 
candidates have been proposed in clinical and experimental cell transplantation e.g. 
bone marrow mononuclear cells, mesenchymal adult progenitor cells, cardiac 
progenitor cells and skeletal myoblasts1. Umbilical cord blood (UCB) derived cells 
have the advantage of  being easy to obtain in large numbers, which is especially 
important for the sick and elderly population because they may have impaired stem 
cell numbers and their cells may have a decreased capacity for proliferation and 
differentiation 2. Together with their presumed hypoimmunogenic properties, UCB 
holds great potential to facilitate cardiac regeneration after myocardial infarction.  
 
UCB in routine clinical use 
 
Allogeneic hematopoietic stem cell transplantation has been firmly established as an 
important treatment modality for advanced hematological diseases. However, 
allogeneic transplantation has been limited by the availability of suitable related and 
unrelated donors. Hematopoietic progenitor cells can be harvested from the donor 
bone marrow, from mobilized peripheral blood, and such progenitors can also be 
found in UCB. Although the first transplantation was reported more than a decade 
ago, UCB is still considered a relatively novel source of hematopoietic progenitor cells. 
The first clinical application of UCB was reported in 1972 when American scientists 
transfused fetal cord blood cells into a 16-year old boy with acute lymphoblastic 
anemia. He received UCB units from 8 different donors from which one unit engrafted 
successfully and lasted 38 hours3. The first successful transplantation had to wait until 
1989 in the treatment of a child with Fanconi’s anemia4. Since then, regeneration of 
hematopoiesis by UCB is considered as a valuable alternative source for bone marrow 
derived stem cells, especially in pediatric patients. The relatively low number of 
progenitor cells in UCB has long limited the use mainly to pediatric patients, but the 
development of UCB transplantation in adults with hematological disorders is now 
rapidly evolving. Recent comparative studies have suggested that outcome after UCB 
transplantation compares well to outcome after volunteer unrelated donor 
transplantation5,6. However, major challenges of UCB transplantation in adults still 
include better approaches to improve engraftment, reduce the incidence of graft 
versus host disease and improve immune reconstitution7. Apart from the presence of 
hematopoietic progenitor cells, UCB may contain other progenitor cells, including 
mesenchymal, endothelial stem cells, and neuronal precursor cells. The combination 
of hematopoietic and mesenchymal stem cells as well as endothelial progenitors and 
the presumed hypo-immunogenicity of UCB sparks hope for the future of stem cell 
mediated tissue regeneration. To date clinical trials on the use of UCB in non 
hematopoietic disorders are scarce, but experimental data hold promises for the 
future. In neurology, UCB have been  identified as candidates for tissue regeneration 
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in a range of neurodegenerative disorders8. In comparison, in the field of cardiology 
recent evidence for possible tissue regeneration in vitro of several cardiac cell types 
like heart valves9,10, blood vessels9 and cardiomyocytes11 have lead to an increased 
interest in UCB.  
 
Studies in animal models 
 
In the last three years ten preclinical studies12-21 have been published in which UCB 
derived cells were studied in the heart (Table 1). All but one18 evaluated the effect of 
UCB derived cell injection in a MI model. MI was induced by a permanent occlusion of 
the left anterior descending coronary artery12-17,19-21 or by cryoinfarction20. Cells were 
administered intramyocardially12-15,18-21 or intravenously16,17,20. Table 1 shows that 
studies used different derived umbilical cord blood cells and injected different 
numbers of cells at various time points. The variety of experimental models can 
explain the equivocal effects of cell therapy after MI. In only two studies15,17 a baseline 
measurement of left ventricular (LV) function after MI but before stem cell injection 
was performed. In previous studies in mice and rats a significant decrease in infarct 
size was observed in cell treated animals12,13,16,19-21. Furthermore, a significant 
improvement in ejection fraction12,13,19 or fractional shortening14,17, which was 
measured with echo, was observed in UCB derived cell treatment in rodents in all but 
two studies 20,21. Only one study14 reported a positive effect of UCB on LV remodeling. 
In several studies histology showed a higher capillary density12,14,16,19,20 in cell treated 
animals compared to controls, however this finding was not observed by Leor et al.17.  
In our laboratory MI was induced in 12 swine by proximal PTCA balloon 
occlusion of the left circumflex coronary artery for 2 hours followed by reperfusion22. 
Five additional swine were used as healthy controls to assess normal cardiac growth 
and function. One week after MI a baseline MRI was performed on all swine to assess 
LV function and infarct size. The next day, 6 of the MI swine received an intracoronary 
injection of ~100x106 umbilical cord blood derived cultured unrestricted human 
somatic stem cells (USSC) in 10 mL unconditioned culture medium. The other 6 MI 
swine received 10 mL medium intracoronary. Cells or medium were injected slowly (1 
mL/min) in the infarct related artery. Four weeks later all animals underwent a 
second MRI to asses the effect of USSC treatment. The pigs were sacrificed afterwards 
and the hearts were examined by histology. All swine received 8 mg/Kg/day 
Cyclosporine A, starting one week after MI.  
Four weeks after USSC injection in this porcine model of reperfused MI, we 
could not detect a beneficial effect of USSC treatment on global or regional LV 
function. Furthermore, there was no reduction observed in infarct size as measured 
with delayed enhancement MRI compared to medium only treated animals. Infarct 
size actually increased slightly after USSC injection. Histology showed a transmural 
infarct in all MI-swine, containing abundant collagen and fibrous tissue. In USSC 
treated swine an increased number of calcifications and inflammatory cells (CD3+ and 
CD45+) were detected. Immunohistochemistry showed that four weeks after injection 
USSC had not transdifferentiated into a cardiac or vascular phenotype. However, 
some USSC had become CD45 positive. 
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The different results between the preclinical studies predominantly performed 
in small rodents and in our own laboratory, can be explained by the differences 
between the experimental models (Table 1). Differences in heart size, heart rate and 
hemodynamics between large mammals such as the pig and rodents could account for 
the differences found in cell therapy. Ours was the only study that created an infarct 
model with reperfusion, which closely matches clinical settings, but creates a very 
different environment for the injected cells. Furthermore, we injected cells 
intracoronary instead of intramyocardial or intravenously. The different infarct model 
and method of cell delivery we used could account for the differences observed after 
UCB cell therapy.  
There are also large differences between the different UCB derived cell types 
which were injected in the studies; freshly isolated mononuclear cells13,16,20, 
cryopreserved mononuclear cells21, CD34+ cells14 and CD133+ cells17,20 were used but 
also cultured mononuclear cells12, mesenchymal stem cells18, CD34+19 cells and 
USSC15. Furthermore the number of injected cells, the timing of cell injection and the 
follow-up time differ between the studies. Taken together all these differences in 
experimental setup could be the reason why our results contradict earlier reports of 
the effect of UCB on myocardial infarction. 
  The study by Kim et al.15, which was also performed in swine, showed a 
beneficial effect on LV function of the same USSC cell line as used in our studies. 
However, in that study cells were injected intramyocardially, and furthermore, the MI 
was created by permanent LAD ligation. To get more insight in the contradicting 
findings between the study of Kim et al.15 and our study we performed some additional 
experiments. We chose to inject cells into the healthy myocardium in five swine and 
sacrificed the animals four days later.  
 
Figure 1: A. Hematoxylin-Eosin staining 4 days after USSC injection in normal myocardium. Note the 
extensive fibrosis and calcification. Arrows indicate surviving myocytes. B. Hematoxylin-Eosin staining of 
an occluded vessel (between black lines) 4 days after USSC injection in normal non-ischemic 
myocardium.  
 
Extensive micro infarctions (Figure 1A) were observed four days after USSC injection 
in non-ischemic myocardium caused by occluded vessels (Figure 1B). In situ 
hybridization showed that the cells in the occluded vessel were predominantly of 
human origin. Micro infarctions were also observed by Vulliet et al.23 after 
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intracoronary injection of cultured mesenchymal stem cells in dogs. These findings 
suggest that intracoronary injection of these cultured USSC is not suitable, and 
intramyocardial injection might be preferable. Further studies are required to 
investigate whether USSC occlude vessels due to their large cell size (~20 µm). Bone 
marrow derived mononuclear cells, however, are only ~5-7 µm in size.   
In some studies immune suppression was administered to the animals14,15,18. Min et 
al.18 showed that 7 days after injection, human cells could not be detected anymore in 
rats that did not receive immune suppression. With immune suppression human UCB 
derived cells could still be detected 8 days after injection. Three other studies16,17,20 
have shown that after injection of human cells in rodents, these cells could be detected 
in the heart of some but not all of the injected animals. Overall, it is still unclear 
whether UCB cells are really hypo immunogenic. Kim et al.15 even observed a higher 
number of CD3 positive cells and macrophages in UCB treated swine. But they could 
also detect human cells that were positive for cardiomyocyte specific markers such as 
troponin I and myosin heavy chain. Except for the study of Henning et al21, all other 
preclinical studies showed that the human UCB derived cells were detected near 
vessels and cardiomyocytes or myofibroblasts, but the injected cells predominantly 
kept their hematopoietic phenotype.  
  
Conclusions 
 
Treatment of infarcted myocardium with UCB derived cells is promising but there 
should be caution when using these cells in patients. The results of our own 
experiment suggest that intracoronary injection of cultured UCB derived stem cells is 
not suitable. More studies in large animal models with reperfused MI are needed to 
investigate the optimal mode of administration for these cells. Furthermore, since the 
immunogenicity of these cells is not yet determined, this should be tested in 
appropriate models.  
 Since an infarct area is a very hostile environment for injected cells due to 
ischemia and inflammation, it is not surprising that very few cells seems to survive 
and that thusfar limited evidence exists that injected cells are able to differentiate 
towards a cardiomyocyte-like phenotype. Potential approaches to overcome these 
limitations might be the overexpression of survival genes or to direct the 
differentiation of the UCB cells towards a cardiac lineage before injection. 
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Abstract 
 
Objective Regeneration of infarcted myocardium by injecting stem cells has been 
proposed to prevent heart failure. We studied the i.c. administration of human 
umbilical cord blood stem cells (USSC) in a porcine model of myocardial infarction 
(MI) and reperfusion. 
 
Methods In 15 swine, MI was induced by balloon-occlusion of the circumflex coronary 
artery (LCX) for two hours followed by reperfusion. Five swine served as healthy 
controls. One week later, magnetic resonance imaging (MRI) was performed to assess 
left ventricular (LV) function and infarct size. Then, under immune suppression, 6 of 
the 12 surviving MI swine received intracoronary injection of ~108 human USSC in the 
LCX while the other MI-swine received medium. Four weeks later all swine underwent 
follow-up MRI, and were sacrificed for histology. 
 
Results One week after MI, end-diastolic volume (92±3 mL) and LV mass (75±2 g) 
were larger, while ejection fraction (42±2 %) was smaller than in healthy control 
(68±3 mL, 66±3 g and 55±3 %, P<0.05). Regional wall thickening (-7±2 %) in the LCX 
area became akinetic. No difference in global and regional LV function at five weeks 
was observed between MI animals receiving USSC or medium. Infarct size after USSC 
treatment was significantly larger (8±2 g vs. 20±3 g, P<0.05). USSC survived only in 
the infarct border zone at 5 weeks and did not express markers of cardiomyocyte or 
endothelial phenotype. Histology showed that intracoronary injection of USSC caused 
micro infarctions by obstructing blood vessels. 
 
Conclusion In swine with a one week old MI, injection of USSC via the intracoronary 
route doesn’t improve LV function four weeks later. 
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Introduction 
 
Tissue regeneration after myocardial infarction (MI) via stem cell transplantation has 
shown potential as a novel therapy to prevent left ventricular (LV) remodeling and 
heart failure.1-4 For example, direct injection of autologous skeletal muscle progenitor 
cells into the infarcted myocardium, resulted in improved LV function after MI in 
experimental studies5 as well as in patients with an old MI and chronic heart failure.6 
Beneficial effects on LV function have also been reported for bone marrow derived 
stem cells7. Thus, in a large number of studies performed in small animal models of 
MI produced by permanent coronary artery ligation, injection of cells within hours 
after ligation (either intravenously or directly into the infarcted area) attenuated LV 
remodeling and dysfunction.1,2  Clinical studies also showed similarly favorable, albeit 
smaller, effects of autologous bone marrow derived stem cells (injected into the 
coronary artery supplying the infarcted but reperfused myocardial region) on LV 
function after MI,7-11 although more recent evidence suggests that the beneficial effects 
at 6 months were no longer significantly different from controls at 18 months.11  
Although transplantation of autologous cells has the obvious advantage of lack 
of rejection, therapy with autologous cells has also potential disadvantages. First, 
autologous cells are harvested from MI patients, who are likely to have risk factors 
that are associated with decreased precursor cell functionality.12 In addition, the 
number of stem cells obtained during harvesting may be variable, resulting in non-
standardized re-injections12 or necessitating subsequent culture steps, particularly in 
the case of skeletal myoblasts.5,6,13 
Human umbilical cord blood is a rich source of stem cells for hematopoietic 
reconstitution and other potential applications in regenerative medicine, especially 
with respect to the recently described Unrestricted Somatic Stem Cells (USSC) from 
human cord blood.14 Recent evidence suggests that  human umbilical cord blood 
derived cells  may have a beneficial effect on LV remodeling and function after MI.15-19 
Importantly, all five studies produced MI by permanent coronary artery ligation, i.e. 
without reperfusion, which clearly differs from the clinical setting. Furthermore, cells 
were injected either intravenously17,18 or directly into the infarcted territory,15,16,19 
whereas the intracoronary injection of bone marrow derived mononuclear cells are 
typically used in more recent clinical post-myocardial infarction studies.11 
Consequently, the present xenotransplantation study was designed to assess in a 
porcine model of reperfused acute MI the effects of intracoronary (i.c.) injection of 
human umbilical cord blood derived cultured USSC19 on regional and global LV 
function, LV geometry as well as infarct size, using magnetic resonance imaging 
(MRI).20 For this study USSC cultured by Kourion Therapeutics were used, this cell 
line was ex vivo described by Kögler et al.14 and exactly the same cell line was used for 
direct intramyocardial injection by Kim et al.19 
 
Material and methods 
 
Experiments were performed in 2-3 month old Yorkshire-landrace pigs, in compliance 
with the "Guide for the Care and Use of Laboratory Animals" (NIH publication 1996) 
and written approval of the Animal Care Committee of Erasmus MC.  
 50
Effect of USSC on LV function after MI 
 
Umbilical Cord Blood Derived Cells 
USSC were established from human umbilical cord blood as described by Kögler et 
al.,14 and were negative for CD14, CD33, CD34, CD45, and express CD13, CD29, CD44, 
CD49e and HLA-I.  
Cell culture and preparation for transplantation was performed by Kourion 
Therapeutics AG (Langenfeld, Germany) according to proprietary methods.14,19 
 
Experimental Protocols 
Protocol I: Cell Injection and Survival 
We first investigated the survival of human USSC in infarcted porcine myocardium in 
a pilot group of 4 swine. For this purpose, animals were sedated (ketamine 20 mg/kg 
intramuscular (i.m.), and midazolam 1 mg/kg i.m.), anesthetised (thiopental, 12 
mg/kg intravenously (i.v.)), intubated and mechanically ventilated with a mixture of 
oxygen and nitrogen (1:2 vol/vol). Anesthesia was maintained with fentanyl (12.5 
µg/kg/h, i.v.) and isoflurane (0.6-0.8% started after onset of occlusion). Subsequently, 
animals received antibiotic prophylaxis (200 mg procainebenzylpenicillin and 250 mg 
dihydrostreptomycinesulfate i.m.) and underwent coronary catheterization through 
the carotid artery approach, followed by balloon occlusion of the proximal left 
circumflex coronary artery (LCX) for 2 hr followed by reperfusion. Heparin was 
administered every hour (5000 Units). 
One week after MI, swine were anesthetized and heparinized as described 
above and received an i.c. injection of ~ fifty million DAPI-labelled USSC (Sigma-
Aldrich, Schnelldorf, Germany) suspended in 10 mL Dulbecco’s Modified Eagle’s 
Medium (DMEM) in the infarct related artery. USSC were filtered (100 µm pore size) 
and injected slowly (1 mL/min) into the coronary artery perfusing the MI area using a 
delivery catheter (Multifunctional Probing, Boston Scientific Co, Boston, MA). The site 
of injection was identical to the position of the occlusion balloon during MI induction. 
To prevent hyper-acute rejection, two out of the four swine received 600 mg 
mycophenolic acid mofetil (Novartis, The Netherlands) 6 hours prior to cell injection 
followed by 600 mg b.i.d. starting 24 hours after injection, and cyclosporine A (CsA, 
Novartis, The Netherlands) 4 mg/kg b.i.d. starting 24 hours after cell injection. The 
other two animals did not receive immune suppression.  Four days after cell injection 
animals were sacrificed for histological and immunocytochemical analyses. 
 
Protocol II: Effect of USSC on LV Remodeling, Global and Regional Function and 
Infarct Size 
Experiments were performed in 21 swine. Six swine served as healthy controls for 
normal cardiac growth and function. Fifteen swine underwent MI as described above; 
3 swine died within 24 h post-MI due to arrhythmias. One week after MI, swine were 
again anesthetized as described above and underwent magnetic resonance imaging 
(MRI) to assess LV geometry and global and regional function, and infarct size. One 
control animal did not recover from anesthesia. Subsequently, MI swine were 
randomized to receive an intracoronary injection of ~ 100 million USSC suspended in 
10 mL DMEM (n=6), or 10 mL DMEM (n=6). All swine (including that receiving 
medium and the controls) received 300 mg prednisone 24 hours before cell or 
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medium injection followed by 300 mg daily for 2 days. In addition, swine received CsA 
4 mg/kg b.i.d. starting 24 h after cell or medium injection until sacrifice. Four weeks 
later all 17 swine underwent follow-up MRI, after which animals were sacrificed for 
histological and immunocytochemical analyses of the LCX perfused infarct area and 
remote areas of the LV. 
 
Magnetic Resonance Imaging 
Data Acquisition 
A clinical 1.5-Tesla MRI with a dedicated cardiac four element phased-array receiver 
coil was used for imaging (Signa CV/i, GE Medical systems, Milwaukee, WI, USA). 
Repeated breath-holds and gating to the ECG were applied to minimize the influence 
of cardiac and respiratory motion on data collection. Baseline and follow-up contrast 
enhanced (ce) MRI protocol consisted of cine-MRI and Delayed Enhancement (DE) 
imaging. Cine-MRI was performed using steady-state free-precession technique 
(imaging parameters: 24 temporal phases per slice, FOV26-30, rect. FOV 75%, TR 3.4, 
TE 1.4, flip angle 45º, matrix 160x128, bandwidth 83 kHz, 0.75 NEX). To cover the 
entire left ventricle, six to eight consecutive slices of 8 mm were planned in the short 
axis view, perpendicular to the long axis four-chamber view of the left ventricle 
(gap=0). DE imaging was performed to assess total myocardial infarct mass 10-20 
minutes after administration of gadolinium-DTPA (0.5 mmol/kg, Magnevist®, 
Schering) with a 2-dimensional T1-weighted inversion-recovery gradient-echo 
sequence (imaging parameters: slice thickness 8 mm, FOV26-30, rect FOV 75%, TR 
7.3, TE 1.6, flip angle 20 degrees, TI 180-275 ms, matrix 256x192, 1 NEX, bandwidth 
17.9 kHz). The inversion time was adjusted per animal to null the signal of remote 
myocardium. Locations were copied from the cine-images.  
 
Image Analysis 
The MR images were analyzed with dedicated cardiac software (Cine display 
application 3.0, General Electric medical systems, USA). End-diastolic volume (EDV), 
end-systolic volume (ESV) and left ventricular weight (LVW) were measured by 
manually drawing the endocardial and epicardial borders in the end- diastolic and 
end-systolic image of each slice. Stroke volume (SV= EDV-ESV), ejection fraction 
(EF= [SV/EDV]x100%) and cardiac output (CO= SVxHR) were computed. End-
diastolic wall thickness (EDT) and end systolic wall thickness (EST) was measured and 
expressed in millimeter in 36 sections per slice. Regional systolic wall thickening 
(SWT) was calculated as [EST-EDT]/EDTx100%. Baseline and endpoint scans were 
matched for location using anatomical landmarks like insertion of the right ventricle 
to the septum and the papillary muscles.20 The volume of DE was quantified by 
manually selecting the enhanced regions from the consecutive 2D slices encompassing 
the left ventricle. DE volume was multiplied by 1.05 g/ml to obtain myocardial infarct 
mass (1 millilitre corresponds to 1.05 gram as measured in our own laboratory). The 
anterior and posterior sections immediately adjacent to the akinetic infarct region 
were defined as border zone. 
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Histology and Immunohistochemistry 
The hearts were excised and cut in 6-8 transverse slices similar to the MRI short axis 
slices. From the basal plane the first ring, and all other odd rings, were fixed in 4% 
buffered formaldehyde and embedded in paraffin. The second ring, and all other even 
rings, were embedded in tissue tec OCT and frozen in liquid nitrogen. Sections (5 µm) 
were stained with hematoxylin eosin (HE), resorcin-fuchsin (RF, collagen), von Kossa 
(calcium). Immunohistochemistry was also performed for identification of porcine 
leukocytes (CD45, Serotec, Kidlington, UK), porcine T-cells (CD3, Abcam, Cambridge, 
UK), human leukocytes (CD45, Chemicon, Hampshire, UK), human endothelial cells 
(vWF, Sigma, Missouri, USA),  human cardiomyocytes (Troponin T, Abcam, 
Cambridge, UK), human mitochondria (MAB1273, Chemicon, Hampshire, UK) and 
USSC (in situ hybridization for human chromosome one with PUC1.77 staining21). 
Sections were semi-quantitatively assessed as negative (–) or extent of 
positivity (+, ++ or +++) for the amount of collagen, calcium deposition, CD45+ cells 
and vascularization. 
 
Statistical Analysis 
Data were analyzed with SPSS 11.0. All data were analyzed using two-way analysis of 
variance (ANOVA), followed by one-way ANOVA and post-hoc analysis using 
unpaired t-testing with Bonferoni correction to test for significant intergroup 
differences at corresponding time points. Intragroup differences between baseline and 
endpoint were determined using paired t-testing with Bonferoni correction. Effect of 
USSC therapy was tested using analysis of co-variance (ANCOVA) with baseline values 
as covariate. Statistical significance was accepted when P≤ 0.05 (two-tailed). All data 
are presented as mean ± SEM. 
 
Results 
 
Cell Injection and Survival 
DAPI labeled cells could be detected 4 days after injection into infarcted area 
both in the presence (Figure 1A) or absence (Figure 1B) of immune 
suppression. Mononucleated USSC were also detected with PUC 1.77 staining 
(Figure 1C) thereby excluding cell fusion. Histological analysis using HE, RF, 
and CD45 staining, showed similar numbers of fibroblasts, collagen deposition 
and inflammatory cell infiltration at 4 days after USSC injection in swine that 
did not, as compared to animals that did, receive immune suppression. 
 
Effect of USSC on LV Remodeling, Global and Regional Function and 
Infarct Size 
Twenty-one animals entered the study. Four animals died prematurely, three of which 
died within 24 hours after induction of MI. One control animal did not recover from 
anesthesia after the baseline MRI, therefore five control swine completed the protocol. 
In all surviving MI animals (n=12), USSC or medium infusion was successful. 
 
LV Remodeling and Global Function 
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One week after MI, significant LV remodeling as demonstrated by a higher end-
diastolic volume (97±5 mL vs. 68±4 mL in control swine), end-systolic volume (54±3 
mL vs. 32±3 mL) and LV weight (75±2 g vs. 66±3 g) in MI swine compared to control 
swine (all P≤0.05; Table 1 and Figure 2) had already occurred. LV remodeling was 
accompanied by LV dysfunction resulting in a lower ejection fraction (42±2 % vs. 
55±4 %, P≤0.05), but not in overt heart failure, as stroke volume (38±2 vs. 37±3 mL) 
was maintained (Table 1). LV-volumes increased between 1 and 5 weeks, but that was 
likely due to growth of the animals, since also the volumes in the control group 
increased (Figure 2). Importantly, the increases in LV weight and volumes over the 4 
week follow-up period were not significantly different between medium- and USSC-
treated MI swine. Furthermore, ejection fraction remained constant over the 4 week 
period in both medium- and USSC-treated animals (Table 1 and Figure 2). 
 
 
Figure 1 DAPI labeled USSC detected 4 days after injection into infarcted LCX region  either with 
(photomicrograph A) or without (photomicrograph B) immunesuppression. Photomicrograph C shows 
the presence of USSC as being positive for PUC1.77 (black dots indicated by black arrows) in an animal 
not receiving immunesuppression. Each bar represents 100 µm. 
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Table 1: Hemodynamic and anatomical data 
MI Swine 
 
Control 
Swine 
(n=5) 
Medium  
(n=6) 
USSC  
(n=6)   
BW (Kg) Baseline 23 ± 1 24 ± 1 26 ± 0.4† 
  Endpoint 35 ± 1* 38 ± 1* 39 ± 1*† 
HR (bpm) Baseline 108 ± 4 91 ± 5† 84 ± 5† 
  
Endpoint 83 ± 5* 93 ± 10 76 ± 5 
SV (mL) Baseline 37 ± 3 39 ± 2 38 ± 2 
 
Endpoint 58 ± 5 57 ± 6 59 ± 5 
LVW (g) Baseline 66 ± 3 76 ± 3† 74 ± 2† 
  Endpoint 99 ± 6* 104 ± 5* 119 ± 5*
§ 
Infarct size (g) Baseline  -  9 ± 3 14 ± 3 
 Endpoint 
 -  
8 ± 2 20 ± 3*‡§ 
Infarct size  Baseline  -  12 ± 3 19 ± 3 
(% of the LV) 
Endpoint  -  7 ± 2** 17 ± 2‡§ 
BW = body weight; HR = heart rate; SV = stroke volume; LVW = left ventricular weight; Baseline = 1 wk post-MI; 
Endpoint = 5 wk post-MI. *P<0.05, **P=0.08 endpoint vs. baseline, †P<0.05 vs. corresponding Control, ‡ P<0.05 
USSC vs. corresponding medium-treated MI animals, § P<0.05 change from baseline USSC- vs. medium-treated MI 
animals. 
 
Regional LV Function 
Analysis of regional LV function at 1 week post-MI showed akinesis of the infarcted 
lateral wall resulting in complete loss of systolic wall thickening in the central infarct 
zone (-7±2%) and partial loss of systolic wall thickening in the border zones (25±3%) 
as compared to systolic wall thickening of the lateral wall in control swine (62±7%; 
Figure 3). The abnormalities in regional function remained virtually unchanged 
during the next 4 weeks of the follow-up period. Furthermore, no differences were 
observed between medium- as well as USSC-treated animals in end-diastolic wall 
thickness or absolute or percent systolic wall thickening, either at baseline or 4 weeks 
after treatment (Figure 3). 
 
Infarct Size 
DE-MRI showed that at 1 week post-MI, the infarcted region encompassed 16±3% of 
LV weight (Table 1). During the 4 week follow-up period, the absolute weight of the 
infarcted region remained constant in the medium-treated swine, and considering the 
increase in total LV weight the relative infarct size thereby tended to decrease (from 
12±3 % to 7±2 %; P=0.08). In contrast, in the USSC-treated swine absolute infarct size 
actually increased slightly and relative infarct size did not decrease. This change in 
infarct size over the four week period between the groups was statistically different 
(P<0.05). 
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Figure 2 LVend-diastolic volume (EDV), LVend-systolic volume (ESV), and LV ejection fraction (EF) at 
baseline (open bars) and at endpoint (solid bars) in Control swine, and MI swine receiving either medium 
or USSC. *P<0.05 endpoint vs. baseline, †P<0.05 vs. corresponding control. There were no differences 
between USSC- and medium-treated MI animals either at baseline or endpoint, or in the response over 
the 4 week follow-up period. 
 
Histology 
Histology confirmed the presence of transmural infarcts in the LCX region with a 
nearly complete loss of viable tissue in all MI animals (Figure 4A and 4B), matching 
the DE scans performed at 5 weeks after MI. The medium- and USSC-treated swine 
both showed abundant collagen (Figure 4C and 4D) and fibrous tissue (Figure 4E and 
4F) in the center of the infarct. The amount of calcification (4A, B) and inflammatory 
cell infiltration (4G, H) appeared larger in USSC-treated compared to medium-treated 
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swine. There were no discernible differences in histological appearance within the 
border zones between USSC- and medium-treated swine.  
 
 
Figure 3 End-diastolic wall thickness (EDT, upper panel), absolute SWT (middle panel) and percent 
SWT (lower panel) at baseline (open bars) and at endpoint (solidbars) in Control swine, and MI swine 
receiving either medium or USSC. *P<0.05, **P<0.1 endpoint vs. baseline, †P<0.05 vs. corresponding 
control. There were no differences between USSC and medium treated MI animals. 
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Figure 4 Infarct area of medium-treated (A, C, E, G) compared with USSC-treated (B, D, F, H) swine, 
showing transmural infarction (photomicrographs A, B; von Kossa staining; arrows point indicate 
endocardium), and abundant collagen (arrows in C, D; RF staining) and fibroblasts (arrows in E, F; HE 
staining), and inflammatory cells (arrows in G, H; panleucocyte marker CD45). The + symbols denote the 
degree of calcification (A, B), collagen (C, D), vascularization (E, F) and CD45+ cells (G, H). Bars denote 1 
mm (A, B) and 300 µm (C–H). 
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Figure 5 CD3 positive cells (brown) in the infarct area of medium treated swine (A) and USSC treated 
swine (B). 
 
CD3 staining showed that more CD3 positive cells were detected in animals 
which were treated with USSC compared to the medium treated animals (Figure 5). 
Immunohistochemistry double labeling with human anti-mitochondria 
antibody showed that USSC were negative for von willebrand factor (Figure 6A) and 
for cardiac troponin T (Figure 6C). Some USSC however were positive for CD45 
(Figure 6B).  
Using PUC1.77 staining we could not demonstrate the presence of USSC in the 
central infarct zone. However, a few USSC (2.0 ± 0.6 cells/cm2) could be detected in 
the border zone (Figure 7), which corresponds with 0.026% of the injected cells. 
 
Discussion 
 
The present study investigated the effects of intracoronary injection of USSC in a 
porcine model of reperfused MI. USSC were injected 1 week after reperfusion and 
swine were studied 4 weeks later. The main finding is that intracoronary injection of 
USSC does not attenuate MI-induced LV remodeling or ameliorate global and regional 
LV dysfunction. In addition, USSC resulted in a larger infarct size at 4 weeks follow-
up, which was accompanied by increases in inflammatory cells and calcifications in 
the infarct zone compared to medium-treated swine. The implications of these 
findings will be discussed in detail. 
 
Previous studies 
To date a few studies have investigated the effects of cord blood derived cells on post-
MI LV remodeling and dysfunction and infarct size. In rats direct injection of CD34+, 
CD133+ or mononuclear cells from cord blood into viable myocardium, bordering the 
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ischemic region, within 1 hour after permanent coronary artery ligation resulted in 
significantly better LV function at 4 weeks16,17 or 4 months.15 Intravenous injection of 
mononuclear cells from cord blood one day after permanent coronary artery ligation 
in mice was reported to reduce infarct size and enhance angiogenesis in the infarct 
border zone.18 Recently, Kim et al.19 reported in a porcine model of permanent ligation 
induced MI, that USSC directly injected into the border zone of the infarct area 4 
weeks post-MI, resulted in significant reduction in end-diastolic volume and 
improvement of ejection fraction compared to medium-treated swine at 8 weeks post-
MI. In addition, these authors observed a decrease in relative infarct size (as measured 
ex-vivo with planimetry). In contrast to the beneficial effects observed in studies that 
used direct intramyocardial injection in models of non-reperfused MI19, the present 
study fails to reveal a beneficial effect of intracoronary injection of USSC on LV 
remodeling, function and infarct size in a model of reperfused MI, although the 
identical cell line was used. Several reasons could be forwarded to explain the negative 
results in the present study, including timing of USSC administration after MI, 
insufficient duration of follow-up in order to detect beneficial effects, insufficient cell 
survival, and/or route of administration. 
 
 
Figure 6 Picture (A) shows vWF positive cells in red, human mitochondria in green (which are not 
present in this slice) and DAPI in blue. (B) shows a CD45 positive cell in red, human mitochondria in 
green and DAPI in blue. The yellow stain indicates double labeling for CD45 and human mitochondria, 
(C) shows troponin T positive cells in green and DAPI in blue, (D) shows human mitochondria in green 
and DAPI in blue. 
 
Timing of cell administration 
The optimal timing of progenitor cell administration after MI is still incompletely 
understood. Hence, it could be argued that USSC injection 7 days after MI was too 
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early to be effective. However, this is unlikely as previous studies showed favorable 
effects of cord blood cell injection as early as 20-min,16 60-min,15 or 1 day18 after 
coronary ligation. We decided to inject USSC 7 days post- MI, as this approximates the 
time-point of injection that is often used in clinical trials.7-9 Alternatively, one might 
forward that injection of USSC 7 days post-MI was too late to be effective. However, 
this is unlikely as Kim et al.19 showed favorable effects of USSC injection as late as 4 
weeks after ligation. Furthermore, the REPAIR-AMI trial11 suggests that optimal 
results are obtained when cells are injected at least 5 days after MI. Hence the timing 
of administration of USSC cannot explain the observed lack of benefit of USSC on LV 
remodeling, function or infarct size in the present study. 
 
 
Figure 7 PUC 1.77 positive cell (encircled) in the border zone of the MI area in 2 USSC-treated swine. 
 
Follow-up time 
Another reason for the lack of benefit observed in our study could be that the 4 week 
follow-up period was insufficient to allow detection of an effect of USSC 
transplantation. However, previous studies reported positive effects on LV 
remodeling, function, and infarct size as early as three18 or four16,17,19 weeks after MI in 
rats,16,17 mice18 and swine,19 indicating that 4 weeks should be sufficient. 
 
Cell survival 
An obvious concern when administrating human USSC to swine is low cell survival 
due to transplant rejection. USSC are purportedly hypo-immunogenic.22 Furthermore, 
we detected DAPI-labeled USSC in the infarct zone 4 days after injection even in swine 
that did not receive immune-suppression, suggesting the absence of hyper-acute 
rejection.  
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Table 2: Available studies with cord blood derived cells in myocardial infarction 
Author 
Anima
l Type of MI Cell type 
Route of 
injection 
Timing 
of cell 
injection 
Post MI 
FU 
LV function 
 
cells vs. control 
Infarct size 
 
cells vs. control 
Henning et al. Rat LAD ligation MNC i.m. 1 h 4 m EF 69% vs. 51% 9.2% vs. 40% 
Hirata et al. Rat LAD ligation CD34+ i.m. 20 min 4 w FS 31% vs. 24%  
Leor et al. Rat LAD ligation CD133+ i.v. 1 week 1 m ∆FS +42% vs. -39%  
Ma et al. Mice LAD ligation MNC I.v. 1 day 3 w  38.7% vs. 47.8% 
Kim et al. swine LAD Coil USSC i.m. 4 weeks 4 w ∆EF +4% vs. -4% 8% vs. 11% 
Moelker et al. swine LCX 
reperfused 
USSC i.a. 1 week 4 w ∆EF +1.8% vs. 2.6% 17% vs. 7% 
FU= follow up,  m= months, w= weeks, LAD = left anterior descending coronary artery, LCX = left circumflex 
coronary artery, MNC+ mononuclear cells, EF = ejection fraction cell treated animals vs. controls, FS = fractional 
shortening cell treated animals vs. controls, ∆FS = percent change in FS, ∆EF= absolute change in EF 
 
 
Figure 8 HE staining of normal LAD area showing healthy myocardium (A). HE staining of LAD area 4 days 
after injection of USSC demonstrating extensive (micro) infarctions (B), caused by occluded vessels (C, 
transverse cross-section of a vessel, D longitudinal cross-section of a vessel). Arrows indicate surviving 
myocytes. Bars denote 100 µm in A–C. 
 
Nevertheless, we decided to use immune-suppression with prednisolone and CsA in 
our study, because injecting human cells in a pig is by definition a HLA-mismatched 
xenotransplantation. It is well known that even under immune suppression, cells will 
be lost by rejection in leukemia patients receiving cell transplants. 
Using in-situ hybridization for human chromosome 1 (PUC1.77 staining),21 we 
could not detect any USSC in the central infarct zone. However, surviving USSC were 
found in the border zone, at the site where the regenerative capacity of progenitor cells 
is considered most plausible.4,11 Kim et al.19 , who used the same cell line, observed 
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survival of a number of USSC in the implanted area, 4 weeks after transplantation in 
swine, using a dose of CsA of 5 mg/Kg/day. In view of the higher dose of CsA that was 
administrated in the present study (8 mg/Kg/day), the low number of USSC found in 
the infarct area in the present study was unlikely the result of rejection due to 
insufficient dosing of CsA. However, immunohistochemistry with CD3 showed that 
more T-cells were present in USSC treated swine compared to medium treated MI 
swine, therefore, there were signs of increased rejection after human USSC injection in 
a porcine MI model even under immune suppression. These findings were also 
observed by Kim et al.19, which used the same cell line in a different experimental 
model. Therefore, the immunogenicity of the umbilical cord blood derived USSC is 
still questionable. 
In the present study swine underwent a 2 hour coronary artery balloon occlusion 
followed by reperfusion to induce MI, which mimics the clinical procedure of 
percutaneous coronary intervention as closely as possible.  Importantly, however, 
previous studies that reported beneficial effects of cord blood derived cells used an 
animal model in which MI was induced by permanent coronary ligation.15-19 It is likely 
that reperfusion results in more abrupt and pronounced inflammation and hence 
creates a more hostile environment that is less appropriate for cell survival during the 
first few days after reperfusion23. In addition, the transmural, inflammatory infarct 
region will not stimulate the undifferentiated USSC to develop into a cardiomyocyte or 
endothelial cell. It is more likely that USSC will develop into  an inflammatory cell-
type, which can contribute to the higher degree of inflammation and calcification 
which was observed in our study. This is why we injected USSC 7 days after 
reperfusion, as it also corresponds with the time of intracoronary injection of 
progenitor cells in clinical studies that reported beneficial effects.8,9  
 
Fate of the injected cells 
Although only a few of the injected cells could be detected four weeks after injection, 
we studied whether these cells have differentiated into a cardiac, vascular or 
hematopoietic phenotype. Immunohistochemistry showed that the injected USSC did 
not transdifferentiate into a cardiomyocyte or endothelial phenotype since they were 
negative for Troponin and vWF. However some of the injected cells were still CD45 
positive meaning that they kept their hematopoietic phenotype, which could mean 
that they contributed to the increased inflammation observed in cell treated animals. 
 
Mechanism: Route of administration causing micro infarctions 
We purposely choose to inject USSC into the coronary artery supplying the infarct 
area, in view of this being the most common route of administration for stem cell 
therapy in the setting of AMI,3 One advantage of intracoronary injection is that cells 
will follow blood flow distribution and reach areas that are well perfused, providing 
oxygen and nutrients to the transplanted cells which will enhance their survival.4 
Conversely, intracoronary injection of cells carries the risk of obstruction of the 
coronary vascular bed. Although this does not appear to be a major issue with purified 
bone marrow cells in most clinical trials, the risk for embolic complications seems to 
be more likely when infusing ex vivo expanded cells. Intracoronary injections of bone 
marrow derived mesenchymal stromal stem cells that were twice the size of freshly 
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harvested bone marrow cells caused micro-infarctions in dogs.24 In the present study, 
USSC increased inflammatory cells and calcification 4 weeks after injection into the 
infarct zone. To further explore the issue of micro-embolization in greater detail we 
injected ~ 50*106 USSC into the LAD of normal hearts in four swine. Four days after 
injection of USSC (which are ~20 µm in size) in normal healthy myocardium, 
extensive micro infarctions were observed in the injected area (Figure 8). USSC could 
be detected in the myocardium obstructing blood vessels. This induction of micro 
infarction may be the mechanism behind the increased infarct size in our USSC-group. 
These results show a potential complication of injection of USSC into the coronary 
circulation. In addition there is evidence that cells expanded in culture show increased 
expression of adhesion molecules compared to freshly isolated cells,25 so that adhesion 
to the endothelium throughout the coronary vascular tree resulted in vascular 
obstruction. Hence, it cannot be excluded that a possible positive effect of USSC 
injection on LV function after MI was thus obscured by the induction of micro-
infarctions caused by the intracoronary injection procedure. In conjunction with the 
positive results obtained with direct intramyocardial injection of the same USSC-cell 
line,19 the present study indicates that intracoronary injection is not the preferred 
route of administration for cultured USSC. Future studies are needed to assess 
whether transendomyocardial injections (rather than intracoronary injections) could 
provide an alternative catheter-based approach to treatment with USSC in reperfused 
MI. 
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Abstract 
 
Aims Stem cell therapy after myocardial infarction (MI) has been studied in models of 
permanent coronary occlusion. We studied the effect of intracoronary administration 
of unselected bone marrow (BM) and mononuclear cells (MNC) in a porcine model of 
reperfused MI. 
 
Methods and Results In 34 swine, the left circumflex coronary artery was balloon-
occluded for two hours followed by reperfusion. Ten swine without MI served as 
controls. All swine underwent magnetic resonance imaging (MRI) 1 week post-MI. The 
next day, 10 of the 30 surviving MI-swine received BM, 10 other MI-swine received 
MNC and the remaining MI-swine received medium intracoronary. Four weeks later 
all swine underwent a follow-up MRI. 
One week after MI, end-diastolic volume (92±16 mL) and left ventricular (LV) 
weight (78±12 g) were greater, while ejection fraction (40±8 %) was lower then in 
controls (69±11 mL, 62±13 g and 53±6 %). Injection of BM or MNC had no effect on 
the MI-induced changes in global or regional LV-function. However, there was a 
significant reduction in infarct size four weeks after MNC injection (-6±3 %), 
compared to medium (-3±5 %). 
 
Conclusions Intracoronary injection of BM or MNC in swine does not improve 
regional or global LV-function 4 weeks after injection. However, a reduction in infarct-
size was noted after MNC injection. 
 
Key words: Myocardial infarction; Bone marrow stem cells; Left ventricular function; 
Magnetic resonance imaging; Infarct size; Swine. 
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Introduction 
 
Regeneration of infarcted myocardium by transplanting bone marrow (BM) derived 
stem cells into the infarct region has been proposed to prevent heart failure by 
angiogenesis and/or myogenesis.1,2 Early experimental studies in animals with a 
myocardial infarction (MI) reported improvements in left ventricular (LV) function 
following cell therapy with bone marrow derived mononuclear cells (MNC),3 or a cell 
sub-population selected from MNC.1 These highly promising initial observations 
sparked a large number of non-randomized clinical trials, reporting beneficial effects 
of MNC therapy on global LV function and myocardial viability.4-8 However, out of 
four recent randomized trials (BOOST-update9, Leuven trial10, REPAIR-AMI11, 
ASTAMI12), three failed to show an improvement in global LV function9,10,12, although 
one reported a reduction in infarct size.10 
In contrast to the discordant results obtained in clinical trials, to date the 
majority of experimental studies reported positive effects of MNC therapy on global 
LV function,3,13-15 although one study reported no effect.16 However, the benficial 
effects of MNC on infarct size, which have been observed clinically,4,6,10  have not been 
investigated in these studies. Furthermore, all studies used a permanent coronary 
artery ligation, while all but one15 (which injected the MNC cells in a coronary venous 
vessel) injected the MNC directly in the peri-infarct area. Hence, these experimental 
studies have a markedly different design compared to the clinical trials. Furthermore, 
most animal studies used more selected, enriched populations, such as the CD34+, c-
kitpos or lin- bone marrow derived cells or bone marrow derived mesenchymal stem 
cells. 
Consequently, we designed an experimental study that matches the clinical 
trial protocols more closely, using a porcine reperfused MI model and intracoronary 
cell injections. For this purpose, we first established cell survival and efficacy of the 
method of cell delivery in several pilot experiments. Subsequently, we studied the 
effect of bone marrow derived cell injection on LV geometry, function and infarct size. 
Myocardial infarction was induced by PTCA-balloon inflation followed by reperfusion. 
LV remodeling as well as global and regional LV function was assessed using cine-
magnetic resonance imaging (cine-MRI). Contrast enhanced MR Imaging (Ce-MRI) 
was used to assess infarct size and infarct remodeling over time. 
Although the clinical trials suggest that intracoronary BM derived cell delivery appears 
safe, recently Yoon et al.17 reported increased calcifications after unselected BM cell 
injection. Therefore we compared the effects of MNC to those of unselected BM. 
 
Methods 
 
Experiments were performed in 2-3 month old Yorkshire-Landrace pigs of either sex 
(n=49), in compliance with the "Guide for the Care and Use of Laboratory Animals" 
(NIH publication 1996) and after approval of the Animal Care Committee of the 
Erasmus MC. 
 
Myocardial infarction  
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Animals were sedated (ketamine 20 mg/kg IM, and midazolam 1 mg/kg IM), 
anesthetised (thiopental, 12 mg/kg IV), intubated and mechanically ventilated with a 
mixture of oxygen and nitrogen (1:2 vol/vol). Anaesthesia was maintained with 
fentanyl (12.5 µg/kg/h) and isoflurane (0.6-0.8% started after onset of occlusion). 
Subsequently, animals received antibiotic prophylaxis (200 mg 
procainebenzylpenicillin and 250 mg dihydrostreptomycinesulfate IM) and underwent 
coronary catheterization through a carotid artery guided by fluoroscopy, followed by 
balloon occlusion of the proximal left circumflex coronary artery (LCX), for 2 hr 
followed by reperfusion. Heparin was administered every hour (5000 Units). 
 
Bone marrow aspiration and preparation 
One week after MI, animals were anesthetised as described above and anaesthesia was 
maintained with 1-1.5% isoflurane. Approximately 40 mL of BM was aspirated from 
the iliac crest, using the same bone marrow aspiration/biopsy needles (Kendall 
monoject, Tyco Healthcare, Gosport, UK) which are routinely used for clinical 
purposes in our hospital. MNC were isolated by Ficoll Paque-plus (Amersham 
Biosciences Europe GmbH, Freiburg, Germany) density gradient separation (25 min 
at 400g) and suspended in 10 mL Modified Eagle’s Medium (MEM). Crude BM (40 
mL) was prepared for injection by filtering through a 100 micron filter. MNC were 
counted using a cell counter (Sysmex CDA 500, Malvern Instruments Ltd, Malvern, 
UK). In view of the identical volume of BM that was aspirated, the amount of MNC 
administered in either group was considere to be similar. BM and MNC were injected 
within one hour after aspiration. 
 
Efficacy of cell delivery 
To investigate the efficacy of cell delivery we tested injection with a selective, non flow-
limiting injection catheter (Multifunctional probing, Boston Scientific Co., Boston, 
MA, USA). One week after MI, bone marrow was aspirated and five swine received an 
intracoronary injection of ~50·106 PKH-labelled MNC (PKH 26, Sigma-Aldrich, 
Schnelldorf, Germany) suspended in 10 mL saline; 5 mL was injected into the LCX 
(infarct area). The other 5 mL was injected into the left anterior descending coronary 
artery (LAD; non-infarct area) to investigate if cell injections cause micro infarctions18. 
MNC were injected slowly (1 mL/min) into the coronary artery perfusing the MI area 
using a probing catheter. The site of injection was identical to the position of the 
occlusion balloon during MI induction. Four days after cell injection animals were 
sacrificed for histological and immunocytochemical analyses. 
 
Functional assessment 
Thirty-four swine underwent MI as described above and 10 swine without MI served 
as controls for normal cardiac growth and function. 
One week after induction of MI, all swine were anaesthetized as described 
above and underwent magnetic resonance imaging (MRI) to assess global and regional 
LV function. Then, 20 of the 30 surviving MI swine were randomized to undergo a BM 
aspiration after which 10 MI swine received an intracoronary injection of ~40 mL 
unselected autologous BM and 10 swine received an intracoronary suspension of 
MNC, a total of ~ 5·108 cells in 10 mL MEM. The remaining 10 MI-swine received an 
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intracoronary injection of 10 mL of MEM. The site of injection was identical to the 
position of the occlusion balloon one week before, and cells were slowly injected into 
the coronary artery (1 mL/min). Investigators were not blinded to treatment. 
Four weeks later, animals underwent follow-up MRI for assessment of LV 
function and infarct size, after which animals were sacrificed for histological analysis 
of the LCX perfused area and remote area of the left ventricle. 
 
Magnetic Resonance Imaging 
Data Acquisition 
A clinical 1.5-Tesla MRI with a dedicated cardiac four element phased-array receiver 
coil was used for imaging (Signa CV/i, GE Medical systems, Milwaukee, WI, USA).19 
Repeated breath-holds and gating to the ECG were applied to minimize the influence 
of cardiac and respiratory motion on data collection. To cover the entire left ventricle, 
six to eight consecutive slices of 8 mm were planned in the short axis view, 
perpendicular to the long axis four-chamber view of the left ventricle (gap=0). DE 
imaging was performed to assess total myocardial infarct mass 10-20 minutes after 
administration of gadolinium-DTPA (0.5 mmol/kg, Magnevist®, Schering).19 We have 
previously shown an excellent correlation between histological (TTC staining) and 
MRI (delayed enhancement) assessment of infarct size.19 
 
Image Analysis 
The MR images were analyzed with dedicated cardiac software (Cine display 
application 3.0, General Electric medical systems, USA).19 End-diastolic volume 
(EDV), end-systolic volume (ESV) and left ventricular weight (LVW) were measured 
and stroke volume (SV= EDV-ESV), ejection fraction (EF= [SV/EDV]x100%) and 
cardiac output (CO= SVxHR) were computed. End-diastolic wall thickness (EDT) and 
end systolic wall thickness (EST) was measured in 18 sections per slice, and regional 
systolic wall thickening (SWT) was calculated as [EST-EDT]/EDTx100%. Baseline and 
endpoint scans were matched for location using anatomical landmarks like insertion 
of the right ventricle to the septum and the papillary muscles.19 
 
Histology and Immunohistochemistry 
The hearts were excised and cut in 6-8 transverse slices similar to the MRI short axis 
slices. From the basal plane the first, third, fifth and seventh slice were fixed in 4% 
buffered formaldehyde and embedded in paraffin. The second, fourth, sixth and eight 
slice, were embedded in tissue tec OCT and frozen in liquid nitrogen. Sections (5 µm) 
were stained with hematoxylin eosin (HE) and resorcin-fuchsin (RF, collagen). 
Immunohistochemistry was performed in the infarct sections to determine the 
expression of the pan-leukocyte marker CD45 (MCA1447, Setotec, Oxford, UK), 
macrophage surface marker (MAC378, Setotec, Oxford, UK), vimentin (Clone DE-R-
11, DakoCytomation, California, USA) and desmin (Clone V9, DakoCytomation, 
California, USA). Desmin is expressed by myocytes and smooth muscle cells; vimentin 
is expressed by fibroblasts and endothelial cells. 
Sections were semi-quantitatively assessed as negative (0) or the degree (from 
1 to 5) of calcium deposition, collagen deposition and vascularization. The infarct 
sections were scored for surface area covered with collagen, calcifications or 
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vascularization. In each animal, 1 section was scored per LV slice (corresponding with 
each of the 5-6 MRI LV short-axis slices). For each section the total infarct area was 
scored (power field 10x). 
 
Statistical Analysis 
Data were analyzed with SPSS 11.0. All data were analyzed using a one-way ANOVA 
and post-hoc analysis using unpaired t-testing with Bonferoni correction to test for 
significant intergroup differences at corresponding time points. Effect of BM and MNC 
therapy at the follow-up MRI was tested using analysis of co-variance (ANCOVA) with 
baseline values as covariate. Statistical significance was accepted when P<0.05 (two-
tailed). All data are presented as mean ± STDEV. 
 
Results 
 
Efficacy of cell delivery 
In three additional in vitro experiments, trypan blue exclusion staining showed that 
99.7% of the cells were viable after the aspiration procedure. Furthermore, following 
subsequent injection through the probing catheter 99.5% of the aspirated cells were 
viable. These results indicate negligible cell loss due to the bone marrow cell 
aspiration and handling. 
 
 
 
Figure 1 PKH-labeled cells do not home to healthy myocardium (A), but PKH positive cells (in red) 
home in infarcted myocardium after injection with a probing catheter (B). 
 
PKH labeled cells could be detected in the infarcted LV lateral wall of 5 swine, 
4 days after injection into the LCX, whereas only a few cells (< 1 cell/cm2) could be 
detected in the healthy non-infarcted LV anterior wall following injection into the LAD 
(Figure 1). Systematic histological analysis did not reveal any myocardial damage in 
the normal LAD-perfused myocardium. Quantative analysis showed that an average of 
248±136 PKH positive cells/cm2 could be detected in the infarct zone, 4 days after 
injection with a probing catheter, corresponding to ~6.5% of the injected cells. 
 
Functional assessment of cell therapy 
Infarct related mortality 
A total of 44 swine entered the study. Out of 34 MI swine, three animals encountered 
ventricular fibrillation during the 2 h occlusion, for which they were treated 
successfully by DC shock. Four animals died prematurely, of which three died within 
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24 hours after induction of MI, while one animal died shortly after the baseline MRI 
(i.e. prior to any therapeutic intervention). Consequently, forty surviving animals 
completed the protocol. 
 
Magnetic resonance imaging  
MI swine had a transmural myocardial infarction of the lateral left ventricular wall 
encompassing 14.7±5% of the left ventricle. There were no differences in body weight 
(BW), stroke volume (SV) or cardiac output (CO) between controls and MI-animals at 
baseline (Table 1). Due to normal growth, BW, SV and CO increased in all four groups 
over the four week follow-up period. Consequently, there were no significant 
differences in BW or systemic hemodynamics during the endpoint scan (Table 1). 
One week after MI, LVW, EDV and ESV were greater, while EF was lower, in 
MI compared to control swine (Figure 2). Changes in LV volumes and mass from 
baseline to four weeks after cell injection did not differ significantly between medium, 
BM and MNC treated MI-animals (Figure 2). 
 
Table 1: Systemic hemodynamics and infarct size measured by delayed enhancement 
  Baseline Endpoint p-values 
     
Control 23±5 40±7  
MI+medium 26±3 43±6  
MI+BM 26±1 43±4 0.669 
BW (Kg) 
MI+MNC 24±1 39±3 0.185 
     
Control 107±15 83±14  
MI+medium 87±16 84±19  
MI+BM 103±23 83±15 0.702 
HR (bpm) 
MI+MNC 85±21 86±17 0.733 
     
Control 37±6 51±8  
MI+medium 38±10 60±11  
MI+BM 36±7 56±9 0.466 
SV (mL) 
MI+MNC 27±9 50±11 0.041 
     
Control 3.9±0.9 4.2±1.0  
MI+medium 3.3±1.0 5.0±1.2  
MI+BM 3.8±1.2 4.6±1.0 0.324 
CO (mL/min) 
MI+MNC 3.2±1.2 4.2±1.0 0.099 
     
Control NA NA  
MI+medium 11.1±5.0 12.3±3.9  
MI+BM 12.0±3.3 11.6±5.6 0.340 
Infarct size (g) 
MI+MNC 10.8±5.5 8.7±4.2 0.045 
     
Control NA NA  
MI+medium 14.3±5.6 11.0±4.2  
MI+BM 14.3±3.6 10.0±4.2 0.236 
Infarct size (%LV) 
MI+MNC 14.3±6.5 8.2±4.2 0.024 
     
BW= body weight; HR= heart rate; SV= stroke volume; CO= cardiac output; Baseline = 1 wk post-MI; 
Endpoint = 5 wk post-MI, %LV = is as a percentage of the left ventricle, P-values= change from baseline 
in BM or MNC vs. medium-treated MI animals, NA= not applicable. Data are mean ± STDEV. 10 
animals per group, except for infarct size (medium n=8, BM n=8 and MNC n=10) 
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One week after MI, there were no significant differences in diastolic wall 
thickness between the different groups (Figure 3). Systolic wall thickening in the LCX 
area was abolished in the MI animals compared to control, which was not affected by 
BM or MNC treatment. Infarct size measured with delayed enhancement revealed that 
MNC treatment resulted in a significant decrease in infarct mass from 10.8±5.5 g to 
8.7±4.2 g, compared to medium treatment (11.1±5.0 g and 12.3±3.9; P=0.045 change 
baseline MNC vs. medium), while BM treatment had no significant effect (Table 1). 
Similarly, there was a greater decrease in infarct size expressed as a percent of the LV 
in the MNC, but not in the BM treated animals, compared to the medium treated 
swine (Table 1, Figure 4). 
 
 
Figure 2 LV end-diastolic volume (EDV), LV weight (LVW), LV ejection fraction (EF) and end-systolic 
volume (ESV) at baseline (solid bars) and at endpoint (open bars) in Control swine, and MI swine 
receiving either medium, BM or MNC. There were no significant differences (all variables P>0.20) 
between BM, MNC and medium-treated MI animals in the response over the 4 wk follow-up period. 
 
Histology 
Histology confirmed that all MI animals had a transmural infarct in the LCX region 
with total loss of viable myocardium, which matched the delayed enhancement scans 
performed at 1 and 5 weeks after MI. All treatments resulted in extensive collagen 
deposition in the center of the infarct (Figure 5). Semi-quantitative analysis showed 
that there were no significant differences in the degree of calcium or collagen 
deposition, or of vascularization (Table 2). Immunohistochemistry showed that most 
of the cells in the infarct area were desmin negative, vimentin positive, CD45 positive 
and occasionally positive for macrophage surface marker (Figure 6), suggesting that 
the majority of cells were fibroblasts (vimentin), inflammatory cells (CD45 and 
macrophage surface marker) and endothelial cells (vimentin). 
 
Discussion 
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Figure 3 End diastolic wall thickness (EDT, upper panel), absolute end systolic wall thickening (SWT, 
middle panel) and percent Systolic wall thickening (SWT, lower panel) at baseline (solid bars) and at 
endpoint (open bars) in Control swine, and MI swine receiving either medium, BM or MNC. There were 
no significant (all variables P>0.10) differences between BM, MNC and medium treated MI animals. 
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Figure 4 Change in infarct size from baseline in percentage of the LV. Regression lines; *P<0.05 vs. 
medium treated MI swine. 
 
The present study investigated the effect of intracoronary injection of MNC or BM on 
left ventricular function and histology at four weeks in a porcine model of acute 
myocardial infarction followed by reperfusion. Our study shows that in swine an 
intracoronary injection of both MNC and unselected BM one week after MI does not 
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improve global or regional indices of LV function four weeks later. In addition, BM 
derived MNC or unselected BM treatment did not reverse the remodeling of the left  
ventricle induced by the MI. However, MNC  reduced infarct size four weeks after 
injection, a finding also reported in the clinical study by Janssens et al.10 
 
 
Figure 5 Infarct area of medium treated (A,B) compared with crude BM (C,D) and MNC (E,F) treated 
swine. HE staining (A,C,E) showed many fibroblasts. RF staining showed a lot of collagen (B,D,F). 
 
Table 2: Semi-quantative histology score 
 
MI+medium  
(n=8) 
MI+BM 
(n=8) 
MI+MNC 
(n=10) 
    
Calcium deposits 0.60±1.31 1.37±1.69 1.04±1.64 
Collagen 3.95±1.10 4.11±0.89 4.36±0.99 
Vascularization 4.05±1.36 3.78±1.22 3.54±1.32 
    
Data are mean ± STDEV. There are no significant differences between groups. 
 
Infarct size reduction 
From the present study we cannot determine the underlying mechanism for the infarct 
size reduction by MNC treatment. Although, it has been shown that BM derived cells 
can differentiate into cardiomyocytes in vitro, it remains unclear whether BM derived 
stem cells are capable of differentiating into cardiomyocytes in vivo,20-22 especially in 
large mammals. Conversely, it has been shown that stem cells engraft in the 
myocardium and induce angiogenesis,23 which could result in improved perfusion, 
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particularly in the border zone. It could be speculated that this might aid in preventing 
further ischemic damage, thereby rescuing viable tissue in the border zone; 
alternatively, the MNC-induced angiogenesis may enhance infarct healing.24 
 
 
Figure 6 Immunohistochemistry showed that cells (brown) in the infarct are desmin negative (A; infarct 
border zone), but vimentin positive (B, infarct border zone in a consecutive section), CD45 positive (C; 
central infarct zone), and that macrophages are present (D; central infarct zone). 
 
Table 3: Overview of preclinical studies on the effects of MNC on global left ventricular function after MI 
 Species MI-model 
Method of 
Injection 
Time of injection 
post MI 
Follow-
up 
# of 
cells 
Effect 
MNC vs. control 
        
Zhang13 Rat LAD ligation i.m. After MI 2 m 5x106 FS +18% vs. -1% 
Ott14 Rat LAD ligation i.m. 1 week 8 weeks 1x107 EF +1% vs. -15% 
Bel16 Sheep LCX ligation i.m. 3 weeks 2 ms 422x106 EF -9% vs. -8% 
Kamihata3 Swine LAD ligation i.m. 60 minutes 3 weeks 1x108 EF +15% vs. +1% 
Yokoyama15 Swine LAD coil I.c. vein 6 hours/2 weeks 4 weeks 3x109 EF +5% vs. -5% 
Moelker Swine LCX occlusion 
reperfusion 
I.a. LCX 1 week 4 weeks 5x108 EF +1% vs. +5% 
MI= myocardial infarction; LAD= left anterior descending coronary artery; LCX= left circumflex coronary artery; m= 
months, FS= fractional shortening; EF= ejection fraction. 
 
Although there was a reduction in infarct size after MNC treatment, this was 
not associated with an improvement in global or regional LV function. This is in 
apparent contrast to the majority of preclinical studies that reported significant 
increases in EF or fractional shortening (Table 3). However, it should be emphasized 
that the experimental protocols in these studies differed considerably from the present 
study. For example, all these studies performed intramyocardial or intravenous cell 
injection in an infarct model of permanent coronary artery occlusion. In contrast, we 
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employed a model that more closely mimics the clinical setting, by using intracoronary 
cell injection in a reperfused MI model, making direct comparison to previous 
preclinical studies difficult. 
Several explanations can be forwarded why cardiac function failed to improve 
after intracoronary injection of MNC or BM in the MI zone. 
 
Timing of cell administration 
Inspection of Table 3 suggests that in permanent ligation MI models, the timing of 
MNC administration does not appear to be critically important. Thus, MNC injections 
either immediately or up to 2 weeks after MI were reported to improve global LV 
function. In contrast, the optimal timing of stem cell delivery in reperfused MI 
remains incompletely understood. However, the REPAIR-AMI trial showed that the 
optimal timing of cell injection appears to be at least five days after MI.25 Also 
Bartunek et al.26 suggest that 3 to 10 days post-MI is the optimal timing of cell therapy. 
We chose to inject cells one week after MI, with the underlying idea that the acute 
inflammatory response is most pronounced shortly after MI, while the inflammatory 
response is diminished one week later, thus creating a better environment for injected 
cells. Therefore, the lack of functional benefit of bone marrow derived cells in this 
study can not be explained by the timing of cell administration. It is likely that a 
proximal two hour during LCX occlusion, followed by reperfusion creates a 
transmural infarct which represents a too hostile environment for injected cells to 
contribute to LV function recovery. 
 
Route of administration 
In contrast to previous experimental studies, which either used intramyocardial or 
retrograde coronary venous injection (Table 3), clinical trials have invariably used 
intracoronary arterial injections of MNC. Intracoronary injected cells are thought to 
disappear from the coronary circulation into liver, lung or kidney within a few hours.27 
Therefore, in clinical trials the intracoronary cell delivery typically involves repeated 
proximal balloon occlusion during cell delivery in order to prevent wash-out of cells 
and facilitate attachment of the injected cells onto the vascular wall.28 We observed 
that only ~6.5 % of the injected MNC were present in the infarcted area 4 days after 
injection, which could be interpreted to suggest that the injection via the probing 
catheter could have resulted in suboptimal cell delivery. Therefore, in 5 additional MI 
pigs, MNC were injected intracoronary via an over the wire balloon catheter during 
repetitive balloon occlusions and pigs were sacrificed 4 days later. These experiments 
yielded a similar number of PKH positive cells (252±144 cells/cm2) in the infarct area 
as with the probing catheter. These findings indicate that injection during balloon 
occlusion does not result in better cell engraftment, and that the low number of MNC 
present in the infarct area 4 days after injection is not the result of the probing 
catheter. 
The cell delivery study showed that injection of MNC in healthy myocardium 
did not induce myocardial damage. In contrast, intracoronary injection of BM derived 
mesenchymal stromal stem cells have been shown to cause microinfarctions18 in dogs. 
No PKH positive cells could be detected in the LAD area (in contrast to the MI area). It 
is important to note that the MNC are smaller in size (5-7 µm as measured with the 
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Sysmex Cell Counter) than cultured mesenchymal stem cells (~20 µm18), and 
therefore MNC are less likely to occlude micro vessels after intracoronary injection. 
 
Follow-up time 
It could be argued that the lack of effect of MNC on global LV function, despite the 
reduction in infarct size, was due to the relatively short follow-up period of 4 weeks. 
However, inspection of Table 3 shows that previous studies in swine did report 
improvement in cardiac function three3,13-15 or four3,13-15 weeks after MNC injections, 
albeit that these were performed in a model of permanent coronary artery occlusion. 
Furthermore, recent clinical trials such as the ASTAMI-trial,12 the BOOST-update9 and 
the trial performed in Leuven10 do not suggest that a longer follow-up will lead to an 
improvement in LV function. Thus, the BOOST-update showed that 18 months after 
MNC administration the intergroup comparison between MNC treated group and 
placebo was no longer significant. The ASTAMI-trial as well as the Leuven trial also 
did not see a beneficial effect on EF or EDV after MNC injection after 6 and 4 months. 
The preclinical study by Dai et al.29 showed a similar trend as the BOOST-update, in 
that the initial positive effect observed at four weeks was lost after six months. Taken 
together, the weight of available evidence from experimental and clinical studies 
suggests that a longer follow-up period may not yield a significant improvement in LV 
function. 
 
Infarct composition 
There were no significant differences between the MI group receiving medium, and 
either BM or MNC with respect to the histology. In all MI swine a transmural infarct 
was observed with transmural loss of viable myocytes. There were no signs of 
cardiomyocyte regeneration since immunohistochemistry showed that all cells in the 
infarct were inflammatory cells, fibroblasts or capillaries. A transmural infarct seems a 
hostile environment for the undifferentiated stem cells in the mononuclear fraction. It 
is not unlikely that MNC will differentiate into fibroblasts in such an environment, and 
therewith contribute to infarct reduction by infarct remodeling i.e. scar contracture, 
but do not contribute to contractility. 
 Yoon et al17 reported that injection of unselected BM aggravated calcifications 
within the infarct zone. Similarly, we observed a trend towards increased calcifications 
following BM administration, but this failed to reach statistical significance (P = 
0.084). Together with the lack of effect of BM on infarct size in the present study, 
these observations support the concept that MNC should be favored over unselected 
BM. 
 
Conclusions 
In a porcine model of myocardial infarction followed by reperfusion, we could not 
demonstrate improvements in global or regional LV-function by injection of BM-
derived MNC. However, we did observe a reduction in infarct size four weeks after 
MNC-injection, which is in accordance with recent clinical observations.10 
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Abstract 
 
Background: Repair of infarcted myocardium by injection of bone marrow derived 
cells has been proposed to prevent heart failure. In most clinical trials, cells were 
injected during repeated balloon occlusion. To evaluate whether injection during 
repeated balloon occlusion is the optimal mode of administration, we injected bone 
marrow derived mononuclear cells (MNC) intracoronary with and without balloon 
occlusion in a porcine model of a reperfused MI. 
 
Methods: In 14 domestic swine, the proximal left circumflex coronary artery was 
balloon-occluded for two hours followed by reperfusion. One week after induction of 
MI, a total of ~100 million MNC labeled with a permanent fluorescent membrane 
stain (PKH 26) were injected. Seven swine were injected using a selective injection 
catheter during normal coronary flow, the other seven swine were injected during 
repetitive balloon occlusion. In all animals, cells were administered in infarcted tissue 
as well as normal non-ischemic myocardium. Ninety minutes (n=4) and four days 
(n=10) later swine were sacrificed for histological analysis. 
 
Results: Ninety minutes and four days after injection, no PKH labeled cells were 
detected in non-ischemic myocardium. However, in infarcted tissue ~6.5% of the 
injected PKH-labeled cells were demonstrated four days after injection. Similar 
numbers of PKH-positive cells were found in the infarct area irrespective of whether 
normal flow or balloon interrupted flow injections were used (249±43 cells/cm2 vs. 
252±42 cells/cm2 P=NS). 
 
Conclusion: Bone marrow derived MNC do not home to normal non-ischemic 
myocardium. Selective injection during uninterrupted flow appears to be as effective 
as injection during repeated balloon occlusion to deliver MNC to the infarcted 
myocardium. 
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Introduction 
 
Improvement of function of infarcted myocardium by injection of bone marrow 
derived cells into the infarct region to prevent heart failure has been demonstrated in 
most pre-clinical and clinical studies. Preclinical studies were predominantly 
performed in models of myocardial infarction (MI) produced by permanent coronary 
artery occlusion. Furthermore, cells were injected directly into the myocardium1 or 
intravenously2, mainly because these studies were performed in small rodents, in 
which intracoronary injection was not feasible. Based on these encouraging initial pre-
clinical reports, clinical trials were initiated, which employed intracoronary (i.c.) 
administration of bone marrow derived cells.3-5 All these trials invariably used the 
method of intermittent balloon occlusion during injection of cells through the wire 
lumen, based on the assumption that this would yield increased adhesion of the 
injected cells to the vascular wall during the non-flow period, thereby leading to a 
higher cell engraftment.6 While this method of cell delivery via intermittent balloon 
occlusion appears to be safe and feasible,7 its superiority in terms of enhancing cell 
delivery compared to cell injection during normal coronary arterial flow was never 
evaluated.  
In light of these considerations, we tested the hypothesis that injection during 
balloon occlusion results in superior grafting of cells as compared to injection during 
normal arterial flow. For this purpose we performed intracoronary injections of bone 
marrow derived mononuclear cells (MNC) during intermittent balloon occlusions and 
during normal coronary blood flow using a selective injection catheter in a porcine 
model of reperfused MI closely mimicking the clinical settings. 
 
Material and Methods 
 
Experiments were performed in 2-3 month old, 20 Kg Yorkshire-landrace pigs in 
compliance with the "Guide for the Care and Use of Laboratory Animals" (NIH 
publication 1996) and after approval of the Animal Care Committee of the Erasmus 
MC.  
 
MNC isolation and labelling 
Approximately 40 mL of BM was aspirated from the iliac crest of the pigs and 
collected in two tubes containing 15 mL buffered phosphate saline (PBS) with 1250 
Units heparin. The BM was washed to remove the PBS and heparin after which MNC 
were isolated using a Ficoll Paque-plus (Amersham Biosciences Europe GmbH, 
Freiburg, Germany) gradient separation (20 minutes at 800 G). The isolated MNC 
were incubated for 5 minutes at 37°C with the permanent fluorescent membrane stain 
PKH26 (Sigma-Aldrich, Schnelldorf, Germany). After washing and centrifuging steps, 
MNC were resuspended in 10 ml PBS. The resultant cell suspension showed >99% 
PKH26 labelling as assessed by fluorescence microscopy. 
 
Viability of cells 
In six in vitro experiments, trypan blue exclusion (Sigma-Aldrich, Zwijndrecht, The 
Netherlands) staining was used to check cell viability. This is based on the principle 
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that live cells possess intact cell membranes that exclude certain dyes, such as trypan 
blue, whereas dead cells cannot. Cells were incubated with 0.4% trypan blue for 3 
minutes at room temperature. Within 5 minutes after incubation cells were counted 
using a Burker-Turk cell counter chamber under the microscope. Viability was tested 
immediately after isolation of the MNC as well as after injection with the different 
injection catheters. 
 
Animal study 
The animal model that we used has been decribed in detail.8 For this study fourteen 
animals were sedated (ketamine 20 mg/kg IM, and midazolam 1 mg/kg IM), 
anesthetised (thiopental, 12 mg/kg IV), intubated and mechanically ventilated with a 
mixture of oxygen and nitrogen (1:2 vol/vol). Anesthesia was initially maintained with 
fentanyl (12.5 µg/kg/h) and continued with isoflurane (0.6-0.8%). Subsequently, 
animals received antibiotic prophylaxis (200 mg procainebenzylpenicillin and 250 mg 
dihydrostreptomycinesulfate IM) and underwent coronary catheterization through a 
carotid artery guided by fluoroscopy, followed by balloon occlusion of the proximal left 
circumflex coronary artery (LCX), for 2 hr followed by reperfusion. Heparin was 
administered every hour (5000 Units). 
One week after MI, swine were sedated and heparinized as described above. 
Anesthesia was maintained with 1% isoflurane and seven swine received an 
intracoronary injection of ~50·106 PKH-labelled MNC suspended in 10 mL saline into 
the LCX (infarct area) and ~50·106 into the non-ischemic left anterior descending 
(LAD) coronary artery. MNC were injected slowly (1 mL/min) into the coronary artery 
during normal coronary flow using a selective, injection catheter (Multifunctional 
Probing, Boston Scientific Co, Boston, MA). The site of the LCX injection was identical 
to the position of the occlusion balloon during MI induction. The seven other MI 
animals were injected during a flow-limiting balloon occlusion, using an over the wire 
PTCA-balloon (OTW Maverick, Boston Scientific Co, Boston, MA). Cells were injected 
into the LAD and LCX in 3-4 short occlusion periods of 3 minutes, followed by 3 
minutes of reperfusion. Angiographic flow was normal before cell injection in all 
experiments. 
Two swine from each group were sacrificed 90 minutes after cell injection and five 
animals per group were sacrificed four days after cell injection with an overdose of 
pentobarbital for histological and immunocytochemical analyses. 
 
Histology and Immunohistochemistry 
Hearts were excised and cut in 6-8 transverse slices of similar thickness. Each slice 
was divided in infarct zone, border anterior, border posterior and remote LV. Each 
sample was embedded in tissue tec OCT and frozen in liquid nitrogen. PKH positive 
cells were counted on sections (5 µm) using fluorescence microscopy. All PKH positive 
cells per section were counted. For each animal three sections were counted per slice. 
Immunohistochemistry was performed for the identification of endothelial 
cells (mouse anti rat CD31, PECAM-1 , BD Biosciences Pharmingen, Alphen aan den 
Rijn, The Netherlands), leukocytes (mouse anti porcine CD45, Chemicon, Hampshire, 
UK), fibroblasts (mouse anti human CD90, Thy-1,  BD Biosciences Pharmingen, 
Alphen aan den Rijn, The Netherlands) and macrophages (mouse anti human LN-5, 
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Sigma, Missouri, U.S.A.). In short, sections were fixed with acetone at 4°C for 10 
minutes. Then, sections were rinsed for 5 minutes with phosphate buffered saline 
(PBS, 0.01M) and blocked with normal goat serum (Serotec, Düsseldorf, Germany, 
1:10 PBS) to prevent non-specific binding of the second antibody for 10 minutes. 
Sections were rinsed again and incubated with the first antibody for 1 hour at 37°C. 
After three thorough rising steps, sections were incubated with the second antibody 
(Pacific Blue goat anti mouse IgG, Molecular Probes, Eugene, USA) for 1 hour at 37°C. 
After three thorough rising steps, sections were mounted with Vectashield hardset 
(Brunschwig, Amsterdam, The Netherlands). 
 
Statistical Analysis 
Data were analyzed with SPSS 11.0. Data were analyzed using two-way ANOVA. 
Statistical significance was accepted when P≤ 0.05 (two-tailed). All data are presented 
as mean ± SEM. 
 
Results 
 
Three trypan blue exclusion staining experiments showed that 99.8% of the MNC were 
viable after the aspiration procedure. After injection through the probing catheter 
99.6% of the cells were viable. The other three in vitro experiments demonstrated that 
99.2% of the MNC were viable after the aspiration procedure and 99.0% of the MNC 
were viable after injection during balloon occlusion. PKH labeling did not affect the 
viability of the cells, since all cells were viable after labeling. 
 
Table 1: average PKH positive MNC 
 
 
Probing catheter Balloon catheter 
   
absolute cell numbers (cells/cm2) 
1.5 hours (n=2) 314±74  325±66 
4 days (n=5) 249±43 252±42 
relative cell numbers (%) 
1.5 hours (n=2) 8.2±1.9 8.5±1.7 
4 days (n=5) 6.5±1.1 6.5±1.1 
   
Data are mean±SEM, there are no significant differences between groups 
 
In remote non-ischemic LAD perfused myocardium, no PKH labeled cells were 
detected either at 90 minutes or 4 days after injection. In contrast, a significant 
amount of PKH-labeled cells could be demonstrated within post-MI tissue 90 minutes 
and 4 days after injection (Figure 1). The numbers of PKH-positive cells in the infarct 
area were similar for both injection methods. Thus, an average of 314±74 PKH 
positive cells/cm2 could be detected 90 minutes after injection during uninterrupted 
flow which corresponds to ~ 8.2±1.9 % of the injected cells (Table 1). After injection 
during repeated interrupted flow 325±66 PKH positive cells/cm2 could be detected 90 
minutes after injection, which corresponds to ~ 8.5±1.7 % of the injected cells. 
Four days after MNC injection, 249±43 PKH positive cells/cm2 could be 
detected after injection with a probing catheter, corresponding with ~ 6.5±1.1 % of the 
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0            Normal flow                Interrupted flow 
  
1,5h 
A. B. 
  
4d 
    C.              D. 
Figure 1: PKH positive cells in the infarct area 1.5 hours (A,B) and 4 days (C,D) after injection using a 
probing catheter (A,C) or a balloon catheter (B,D). Power field 10x. 
 
injected cells. MNC injection with a balloon catheter resulted in an average of 252±42 
PKH positive cells/cm2 four days after injection which also corresponds with ~ 6.5±1.1 
% of the injected cells. 
Immunohistochemistry showed that the injected PKH labeled MNC stained 
negative for macrophages, however PKH positive cells could be detected near 
macrophages. Occasionally PKH labeled cells were positive for CD45, CD90 and some 
PKH labeled MNC could be detected near CD31 positive cells four days after injection 
(Figure 2). 
 
Discussion 
 
The present study was undertaken to test the hypothesis that flow interrupted 
injection of MNC results in better engraftment of MNC in a porcine model of 
reperfused MI. Contrary to this hypothesis, we observed that the method of cell 
delivery via intermittent balloon occlusion does not lead to higher cell engraftment in 
our model as compared to injection during normal coronary inflow conditions. 
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A.        B. 
   
C.        D. 
Figure 2: Photomicrograph A shows a CD31+ blood vessel (blue) and PKH positive cells (red) located 
close to the CD31+ cells. Photomicrograph B shows a CD45+ cell (blue) and PKH positive cells (red). 
Photomicrograph C shows a macrophage (blue) and PKH positive cells (red). Photomicrograph D shows 
CD90+ fibroblast (blue) and PKH positive cells (red) located in between the CD90+ cells 
 
Histology showed that four days after injection, some PKH labeled cells expressed 
leukocyte (CD45) and fibroblast (CD90) markers. The injected cells were not 
internalized by macrophages and were occasionally located near new blood vessels.  
Because the method of intermittent balloon occlusion whereby MNC are 
typically injected in clinical trials was never validated, we compared this flow-limiting 
delivery method with cell injection during normal coronary flow in a porcine model of 
MI. The viability of cells after injection through the different catheters was similar. 
Our study showed that bone marrow derived MNC do not home in non-ischemic 
myocardium. This observation is in accordance to the study by Aiher et al.9 in rats. 
However, in the infarct area more cells could be detected 90 minutes after injection, 
than four days after MNC injection, however, this did not reach levels of statistical 
significance. Initially, 8 % of the injected cells were detected 90 minutes after 
injection, and four days later 6.5% remained in the myocardium with either mode of 
delivery. These findings suggest that the efficacy of intracoronary injection of MNC in 
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the infarct zone is independent of the method of intracoronary delivery in swine one 
week after MI.  
In one of our previous studies8 we used a probing catheter to inject MNC 
intracoronary. We observed a decrease in infarct size, but no effect on left ventricular 
function. Taken together the finding of the present study, using a different mode of 
intracoronary administration of MNC would probably not have had a different effect 
on left ventricular function or infarct size. 
In clinical trials PTCA was thought to thoroughly prevent the backflow of cells 
and at the same time produced a stop-flow beyond the site of the balloon inflation to 
facilitate high-pressure infusion of cells into the infarcted zone and thereby prolong 
contact time for adhesion and potential cellular transmigration of the infused cells 
through the endothelium.10,11 
Although engraftment of injected stem cells was thought to be higher under 
non-flow conditions,6 this was not the case in our study. Apparently a few minutes of 
balloon occlusion are not enough to increase the number of cells that adhere to the 
vessel wall and eventually end up in the myocardium. It cannot be excluded that a 
longer occlusion period, and thus a longer non-flow period might enhance the number 
of adhered cells. However, extending the occlusion duration may increase the 
likelihood of arrhythmias and also induce an additional inflammatory response or 
reperfusion damage.  
The limitation of our study is that no absolute flow measurements were 
performed during and before cell injection.  
 
Clinical relevance 
Our study suggests that it would not change outcome for patients in clinical trials if a 
selective injection catheter would be used instead of a balloon catheter for stem cell 
injections. This potentially prevents additional damage to the vascular wall and 
additional ischemia, created by balloon occlusions.12,13 
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Abstract 
 
Background: Regeneration of infarcted myocardium by injection of stem cells into the 
infarct region has been proposed to prevent heart failure. Intracoronary injection 
appears safe and feasible. However, there have been previous studies that suggest that 
intracoronary injection of cultured cells is associated with ECG-changes and a higher 
in-stent restenosis. We, therefore, compared the effect of intracoronary injection of 
freshly isolated bone marrow derived mononuclear cells (MNC) and cultured MNC in 
a porcine model of a reperfused MI. 
 
Methods: In 10 domestic swine, the proximal left circumflex coronary artery was 
balloon-occluded for two hours followed by reperfusion. One week after induction of 
MI, five swine received intracoronary autologous cultured MNC, a total of ~100 
million cells labeled with the permanent fluorescent membrane stain PKH and five 
swine received PKH labeled freshly isolated MNC. Half of the cells were administered 
in post-MI myocardial tissue and the other 50% of the cells were injected in normal 
non-ischemic myocardium. Four days later all swine were sacrificed for histological 
analysis. 
 
Results: In the non-ischemic myocardium no freshly isolated MNC could be detected 
and the tissue appeared normal. However, after injection of cultured MNC micro 
infarctions were observed in the non-infarcted remote zone. In post-MI tissue a 
significant number of PKH labeled cultured MNC as well as freshly isolated MNC were 
present. 
 
Conclusion: Freshly isolated MNC do not home in non-ischemic myocardium. 
Cultured MNC, which are larger in size (~ 12 µm, vs. 5-7 µm for freshly isolated MNC), 
obstruct blood vessels in healthy myocardium probably due to their larger size, 
thereby causing micro infarctions. 
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Introduction 
 
Myocardial infarction (MI) is still one of the leading causes of morbidity and mortality 
in western society. Regeneration of infarcted myocardium by injection of stem cells 
into the infarct region has been proposed to prevent heart failure. Experimental 
studies in small rodent models showed that stem cell therapy has potential to improve 
left ventricular function after MI. To date, several clinical trials have been completed 
and intracoronary injection seems safe and feasible. However, there have been 
previous pre-clinical studies which suggest that intracoronary injection of cultured 
cells is associated with ECG-changes1 and myocardial injury and a higher in-stent 
restenosis in clinical applications2,3. Intracoronary administration of umbilical cord 
blood derived cells can cause micro infarctions after injection in normal myocardium4. 
Intracoronary delivery of bone marrow derived mesenchymal stem cells was also 
associated with a higher incidence of decreased coronary blood flow5. Bone marrow 
derived cell injection is even believed to induce severe calcifications after 
intracoronary injection6. It is not surprising that injected cells differentiate into 
fibroblasts after injection7 in the scar tissue of a MI in stead of into myocytes.  
Most animal studies are performed in a small rodent model with a permanent 
ligated coronary artery, where cells are injected intramyocardial. These models are not 
able to predict the possible harmful effects of stem cell therapy in patients since heart 
rate, heart size and hemodynamics in rodent are very different from large mammals, 
for example humans. In our study we used a pre-clinical porcine model of myocardial 
infarction followed by reperfusion and thereby more closely mimicking the clinical 
settings of MI. In patients with a MI reperfusion is still the recommended therapy 
according to the guidelines. Therefore, we investigated the effect of intracoronary 
injection of freshly isolated bone marrow derived mononuclear cells (MNC) and 
cultured MNC in a porcine model of a reperfused MI and intracoronary injection of 
the cells into healthy myocardium. 
 
Materials and methods 
 
Experiments were performed in 2-3 month old Yorkshire-landrace pigs, in compliance 
with the "Guide for the Care and Use of Laboratory Animals" (NIH publication 1996) 
and after approval of the Animal Care Committee of the Erasmus MC.  
 
Animal study 
Two groups of animals were compared (Figure 1). 
Five animals were sedated (ketamine 20 mg/kg IM, and midazolam 1 mg/kg 
IM) and approximately 40 mL of bone marrow (BM) was aspirated from the iliac 
crest. MNC were isolated by Ficoll Paque-plus (Amersham Biosciences Europe GmbH, 
Freiburg, Germany) density gradient separation. Cells were plated on flasks and 
cultured in EGM-2 (Cambrex, Biowhittaker, USA) for three weeks. 
 Two weeks after the BM aspiration the above five animals and a second group 
of five swine were sedated (ketamine 20 mg/kg IM, and midazolam 1 mg/kg IM), 
anesthetised (thiopental, 12 mg/kg IV), intubated and mechanically ventilated with a 
mixture of oxygen and nitrogen (1:2 vol/vol) as descibed before4,8. Anaesthesia was  
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Figure 1: BMA= bone marrow aspiration, MI= myocardial infarction, CI= cell injection, †= sacrifice. 
Upper timeline demonstrates the model for the group swine that received the cultured MNC. Timeline at 
the bottom shows the model for the swine that receive fresh MNC. 
 
initially maintained with fentanyl (12.5 µg/kg/h) and continued with isoflurane (0.6-
0.8% started only after onset of occlusion to prevent preconditioning). Subsequently, 
animals received antibiotic prophylaxis (200 mg procainebenzylpenicillin and 250 mg 
dihydrostreptomycinesulfate IM) and underwent coronary catheterization through a 
carotid artery guided by fluoroscopy, followed by balloon occlusion of the proximal left 
circumflex coronary artery (LCX), for 2 hr followed by reperfusion8. Heparin was 
administered every hour (5000 Units). 
One week after MI, all 10 swine were sedated and heparinized as described 
above. Anesthesia was maintained with 1% isoflurane and five swine received an 
intracoronary injection of ~50·106 PKH-labelled cultured MNC (PKH 26, Sigma-
Aldrich, Schnelldorf, Germany) suspended in 10 mL saline into the LCX (infarct area) 
and into the left anterior descending coronary artery (LAD; non-infarct area). MNC 
were injected slowly (1 mL/min) into the coronary artery perfusing the MI area using a 
selective, non flow-limiting probing catheter (Multifunctional Probing, Boston 
Scientific Co, Boston, MA). The site of injection was identical to the position of the 
occlusion balloon during MI induction. The five other MI animals first underwent a 
BM aspiration. MNC were isolated, labeled with PKH, and the same number of cells 
were injected as described above in the LAD and the LCX. 
Four days after cell injection animals were sacrificed with an overdose of 
pentobarbital for histological and immunohistochemical analyses. 
 
Histology and Immunohistochemistry 
The hearts were excised and cut in 6-8 transverse slices. Slices were embedded in 
tissue tec OCT and frozen in liquid nitrogen. Sections (5 µm) were stained with anti-
PCNA (DakoCytomation, California, USA), CD45 (mouse anti porcine CD45, 
Chemicon, Hampshire, UK), vimentin (Clone DE-R-11, DakoCytomation, California, 
USA) and desmin (Clone V9, DakoCytomation, California, USA) antibodies. PCNA is a 
cell proliferation marker, CD45 is a pan-leukocyte marker, desmin is expressed by 
myocytes and smooth muscle cells and vimentin is expressed by fibroblasts and 
endothelial cells. 
 
Statistical Analysis 
       2w                      1w               4d 
                                  1w                4d 
† BMA MI      CI  
Cultured: 
(n=5) 
 † MI      BMA+CI Fresh: 
(n=5) 
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Data were analyzed with SPSS 11.0. All data were analyzed using unpaired t-testing. 
Statistical significance was accepted when P≤ 0.05 (two-tailed). All data are presented 
as mean ± SEM. 
 
Results 
 
PKH labeled MNC could be detected 4 days after injection into infarcted area. 
Quantative analysis showed that an average of 249±43 PKH positive cells/cm2 could 
be detected four days after injection which corresponds to ~6.5% of the injected cells 
(Table 1). 
 
Table 1: number of PKH positive cells 
 # cells/cm2 % of the injected cells 
   
 LCX 
Freshly isolated MNC 249±43 6.5±1.1 
Cultured MNC 173±39 4.5±1.0 
   
 LAD 
Freshly isolated MNC <1 <0.03 
Cultured MNC 88±14 2.3±0.4 
 
Data are mean±SEM, There were no significant differences between groups. 
 
 After MNC culturing 173±39 PKH positive cells/cm2 could be detected four 
days after injection in the infarcted LCX tissue with a probing catheter which 
corresponds in ~4.5% of the injected cells (Table 1). This difference between fresh and 
cultured MNC did not reach levels of significance (P>0.05).  
In non-infarcted remote LAD myocardium, only a few (< 1 cell/cm2) PKH 
labeled freshly isolated MNC could be detected 4 days after injection. Light 
microscopy showed healthy myocardial tissue without signs of injury.  
 
  
A.  B. 
Figure 2: Hemotoxilin-Eosin staining; Photomicrographs A and B shows micro infarctions four days 
after injection of cultured MNC in normal myocardium. Arrows indicate surviving myocytes, bar indicates 
80 µm. 
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In contrast, significantly more cultured MNC (88±14 cell/cm2) were detected 4 
days after injection in non-infarcted myocardium (P<0.05). In addition, after injection 
of cultured MNC in swine micro infarctions were observed in the non-infarcted remote 
zone (Figure 2). 
Furthermore, the freshly isolated MNC were spread homogenous in the 
myocardium perfused by the artery where the cells were injected, however the 
cultured MNC were detected in cell clusters (Figure 3), especially after injection in the 
LAD (Figure 3C). 
Immunohistochemistry showed that the injected cultured MNC were negative 
for desmin and occasionally positive for vimentin and CD45 (Figure 4). The PKH 
labeled cultured MNC were negative for PCNA. There were no differences in histology 
between the different expression of markers in the different areas (LAD or LCX). 
 
  Fresh MNC     Cultured MNC 
   
LCX 
A.          B. 
    
LAD 
C.         D. 
Figure 3: Photomicrograph A and C show PHK labeled cells four days after injection of freshly isolated 
MNC in the infarcted LCX (A) and the non-infarcted LAD (C). Photomicrograph B and D show PHK 
labeled cells four days after injection of cultured MNC in the infarcted LCX (B) and the non-infarcted 
LAD (D). Powerfield 10x 
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A.      B. 
  
C.      D. 
  
E.      F. 
Figure 4: Photomicrograph A and B show desmin positive cells (Blue) and PHK labeled cells (red) 4 days 
after injection of cultured MNC in the non-schemic LAD (A) and the infarcted LCX (B). C and D show 
vimentin positive cells (Blue) and PHK+ cells (red) 4 days after injection of cultured MNC in the LAD (C) 
and the LCX (D). E an F show CD45 positive cells (Blue) and PHK labeled cells (red) 4 days after injection 
of cultured MNC in the non-ischemic LAD (E) and in the infarcted LCX (F). Powerfield 100x. 
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Discussion 
 
The aim of this study was to investigate the effect of cultured and freshly isolated BM 
derived MNC on healthy and infarcted myocardium, since previous studies showed 
harmful side effects of stem cell injection1-7. 
 
Four days after MI, cultured and freshly isolated MNC cells could be detected 
in the infarct area. Our study showed that freshly isolated MNC do not home in non-
ischemic myocardium and there were no changes in the healthy myocardium after 
injection. However, cultured MNC which are larger in size (~12 µm vs. 5-7 µm), 
obstruct blood vessels in healthy myocardium probably due to higher expression of 
adhesion molecules9 on the cells and thereby causing micro infarctions. It could be 
possible that the survival of the cultured cells is lower in the LCX due to additional 
micro infarctions caused by the cell injection. Or that LAD injected cells in the animals 
which were injected with freshly isolated MNC, homed to the LCX, and thereby 
causing higher numbers of cells in the infarcted LCX perfused area. 
 In one of our previous studies4 micro infarctions were also observed after 
injection of cultured umbilical cord blood derived unrestricted somatic stem cells. 
These umbilical cord blood derived cells are even larger in cell size (~ 20 µm) than the 
cultured MNC in this study, and caused more severe micro infarctions with beginning 
calcifications four days after injection in healthy tissue.  
Although clinical trials suggest that intracoronary stem cell injection is safe, 
cultured stem cells should be used with caution when applied intracoronary. It should 
be further investigated what the effect of injection of cultured cells is, when applying a 
different mode of administration, for example intramyocardial cell injection. 
Furthermore, it is important to know what the long term effect is of the induction of 
micro infarctions after intracoronary injection. 
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Abstract 
 
Aims Magnetic resonance imaging (MRI) has been proposed as a tool to track iron 
oxide-labelled cells within myocardial infarction (MI). However, infarct reperfusion 
aggravates microvascular obstruction (MO) and causes haemorrhage. We 
hypothesized that haemorrhagic MI causes magnetic susceptibility-induced signal 
voids that may interfere with iron oxide-labelled cell detection. 
 
Methods and results Pigs (n= 23) underwent 2 h occlusion of the left circumflex 
artery. Cine, T2*-weighted, perfusion, and delayed enhancement MRI scans were 
performed at 1 and 5 weeks, followed by ex vivo high-resolution scanning. At 1 week, 
MO was observed in 17 out of 21 animals. Signal voids were observed on T2*-weighted 
scans in five out of eight animals, comprising 24 +22% of the infarct area. A linear 
correlation was found between area of MO and signal voids (R2= 0.87; P=  0.002). At 
5 weeks, MO was observed in two out of 13 animals. Signal voids were identified in 
three out of seven animals. Ex vivo scanning showed signal voids on T2*-weighted 
scanning in all animals because of the presence of haemorrhage, as confirmed by 
histology. Signal voids interfered with the detection of iron oxide-labelled cells ex vivo 
(n= 21 injections).  
 
Conclusion Haemorrhage in reperfused MI produces MRI signal voids, which may 
hamper tracking of iron oxide-labelled cells. 
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Introduction  
 
Transplantation of cells after myocardial infarction (MI) has emerged as a promising 
therapy to restore heart function.1-4 To evaluate cell engraftment, non-invasive 
tracking of cells with magnetic resonance imaging (MRI) has been proposed as a 
valuable tool. Cells labelled with iron oxide, paramagnetic probes cause a T2* signal 
void5
 
and can thus be detected up to single-cell resolution in vitro.6-8 In vivo, clusters 
of labelled cells could be detected after injection into infarcted myocardium of 
mouse,9-10
 
rabbit,11 
 
and pig hearts.12-17 
However, in clinical practice, acute MI is treated by reperfusion therapy,18 aggravating 
microvascular obstruction (MO) and causing haemorrhage.19,20 Haemoglobin 
degradation products, such as methaemoglobin and haemosiderin, have strong 
magnetic susceptibility effects,21
 
which may mimic the signal voids caused by iron 
oxide-labelled cells.  
We hypothesized that haemoglobin degradation products in reperfused MI produce 
signal voids that interfere with reliable iron oxide-labelled cell tracking. Therefore, we 
evaluated the MRI characteristics of subacute (1 week old) and chronic (5 weeks old) 
infarcts in a porcine model of reperfused MI and compared the MRI findings with 
histology of the infarct tissue.  
 
Methods  
 
Myocardial infarction  
Experiments were performed in 23 Yorkshire–Landrace pigs (2–3 months old, ~25 
kg). The study complied with the regulations of the Animal Care Committee of the 
Erasmus MC and the National Institutes of Health Publication 86–23, revised 1996. 
Animals were sedated (ketamine, 20 mg/kg IM and midazolam, 1 mg/kg IM), 
anaesthetized (thiopental, 12 mg/kg IV), intubated, and mechanically ventilated 
(mixture of oxygen and nitrogen, 1:2). Analgesia was maintained initially with fentanyl 
(12 mg/kg/min IV). Subsequently, animals underwent left coronary catheterization, 
followed by balloon occlusion of the left circumflex (LCx) coronary artery, proximal of 
the first margo obtusus branch. After 2 h, the balloon was deflated and the infarct 
reperfused, as confirmed by TIMI III flow on angiography. Anaesthesia was 
maintained with isoflurane (0.6–0.8%), starting after the occlusion of the LCx.  
 
Magnetic resonance imaging  
A 1.5 T MRI scanner with a dedicated four-element-phased array receiver coil was 
used (Signa CV/i; GE Medical Systems, Milwaukee, WI, USA). One week after MI, pigs 
were anaesthetized and ventilated as described earlier and underwent clinically 
applied,22 electrocardiogram (ECG)-gated cine, T2*-weighted, first-pass perfusion 
(FPP), and delayed enhancement (DE) MRI. The T2*-weighted sequence was applied 
in a subset of animals (n=8 and n=7 at 1 and 5 weeks, respectively) because of 
technical limitations of the scanner software at the start of the study. For detailed MRI 
protocols, see Supplementary material online. Breath-holding was achieved by 
interrupting the ventilation.  
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After scanning, eight animals were euthanized using an overdose of 
pentobarbital. Hearts were excised, immersed in saline, and scanned ex vivo using 
gradient echo (GE) and spin echo (SE) sequences with multiple echo times and flip 
angles to obtain T1-, proton density-, T2-, and T2*-weighted images (T1W, PDW, 
T2W, and T2*W, respectively). For detailed MRI protocols, see Supplementary 
material online. The minimum time interval between in vivo scanning and sacrifice 
was at least 3 h, and in most cases, 12 h (overnight), to make sure that all gadolinium-
DTPA had been washed out.  
One animal died following the 1 week scan. Five weeks after infarction, the 
remaining 14 animals underwent a follow-up MRI using a similar imaging protocol as 
at 1 week. In one animal, at 1 week and again at 5 weeks, no vascular access could be 
assured during scanning for injection of contrast; therefore, in this animal, no FPP 
and DE scans could be obtained. In one animal at 1 week, FPP scanning was not 
reliable for the assessment of MO owing to movement artefacts; therefore, it was not 
included in the analysis. Three infarct specimens were scanned a second time after 
standard paraffin embedding. Finally, of three animals, no ex vivo scans could be 
obtained because of technical limitations during scanning.  
In order to compare signal voids induced by the presence of iron oxide-labelled 
cells and haemoglobin degradation products, ex vivo scanning was repeated after local 
injections with either 0.1, 1, or 4 x
 
106
 
iron oxide-labelled human umbilical vein 
endothelial cells. A total of 21 injections were performed in four subacute and three 
chronic infarct specimens. Cells were labelled as described previously,8 
 
resulting in 
~9.2 pg iron per cell, and fixed in 4% formaldehyde.  
A flowchart (Figure 1) summarizes the protocol and the number of animals 
studied at each time point.  
 
Image analysis  
MR images were analysed using Cine Display Application Version 3.0 (GE Medical 
systems, Milwaukee, WI, USA). Signal voids were identified on mid-papillary, single-
slice T2*W scans, and expressed as a percentage of the infarct area as defined by DE 
MRI. Signal void volumes were calculated by multiplying their area by slice thickness. 
MO was identified on mid-papillary, single-slice FPP images as an area of persistent 
subendocardial hypoenhancement.23 MI was identified on DE images as an area with 
delayed hyperenhancement and its size was expressed as a percentage of the left 
ventricular (LV) wall volume.  
Contrast-to-noise ratio (CNR) was measured in the T2*W in vivo and ex vivo scans at 1 
and 5 weeks, according to the relation [CNR=(SImyo 2 SIvoid)/SDnoise], where 
SImyo represents signal intensity of remote or infarcted myocardium, SIvoid, signal 
intensity of signal voids, and SDnoise, standard deviation of background noise 
measured in the air outside the pig.  
Total haemorrhagic areas were measured at mid-papillary levels in PD-T2*W 
ex vivo scans using Clemex Vision PE analysis software (Clemex Technologies, 
Longueuil, Canada) and expressed as a percentage of the total infarct area.  
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Figure 1 Flowchart of the study protocol. Numbers between brackets indicate the number of animals or 
specimens used at a certain time point. 
 
Histology  
Hearts were transversally cut in ~1 cm thick slices and stained with 1% 
triphenyltetrazolium chloride (37°C, 15 min; Sigma, St Louis, MO, USA) and 
subsequently with Prussian blue (PB), which stains haemosiderin deposits deep blue. 
After standard paraffin embedding, 5 mm serial sections were cut in the same plane as 
the MRI scans. Sections were stained with haematoxylin eosin (HE) or von Kossa’s 
(VK), or restained with PB. VK was counterstained with von Gieson (VG). This 
approach allowed for identification of fat (HE), calcium (VK), collagen (VG), as well as 
haemosiderin (PB). Staining was analysed and compared with matching MR images at 
the same location and imaging plane.  
 
Statistical analysis  
Data are reported as mean±SD. Data from subacute and chronic infarcts were 
compared using paired or unpaired t-testing as appropriate. The correlation between 
area of MO and signal voids was assessed using linear regression analysis, including 
all animals assessed by T2*W scanning. Proportions were compared using a z-test 
(SigmaStat software version 2.03; SPSS Inc., Chicago, IL, USA). Sample size was 
determined with the following assumptions: type I error of 0.05, power of 80%, an 
estimated proportion of animals with an in vivo MRI detectable haemorrhage-induced 
signal void of 35%, based on the literature, with the assumption that a proportion of 
5% would not be relevant. Therefore, eight animals would yield 80% power to detect a 
significant proportion of animals with such a signal void. On the basis of pilot studies, 
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the proportion of ex vivo detected signal voids was estimated to be 90%. A value of 
P<0.05 (two-tailed) was considered statistically significant.  
 
Results  
 
In vivo MRI  
In subacute infarcts, signal voids could be identified in five out of eight animals, using 
the T2*W sequence (Figure 2). In the remaining three animals, signal voids were 
either not observed (n=2) or could not be reliably discerned from the air–heart 
interface susceptibility artefact (n=1). The size of the signal voids was 0.53 +0.51 cm3. 
The area of signal voids comprised 24 +22% of the infarct area. MO was observed in 17 
out of 21 animals, comprising 35 +23% of the infarct area (Table 1). A linear 
relationship was found between the area of signal voids on T2*W scans and the area of 
MO on the corresponding FPP scans at 1 week (R2=0.87; P=0.002; n=8). Infarct size 
was 25 +6% of total LV wall volume (n=22). CNR between remote myocardium and 
areas of signal voids was 27 +16 and between infarcted, non-haemorrhagic 
 
Figure 2 In vivo scans of one animal at 1 week (subacute) and 5 weeks (chronic) after infarction. 
Depicted are the end-diastolic frames of cine, T2*W, FPP, and DE scans at the same level. The infarct area 
is indicated by white arrows. In the T2*W image, endo-and epicardial rims of signal voids are present at 1 
week. The artefact caused by the heart–air interface is indicated by an asterisk. The rims of signal voids 
correspond with a zone of hypo-perfusion in the FPP scan at 1 week, indicating MO. Furthermore, a zone 
of persistent hypoenhancement can be appreciated in the DE scan within the hyperenhanced infarct area. 
At 5 weeks, the area of signal voids in the T2*W image takes up a larger part of the infarct area. Neither 
MO nor an area of persistent hypoenhancement is observed in the FPP or DE scans. Bar indicates 2 cm.  
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Table 1: Results of MRI scanning 
 Subacute infarcts 
(# of animals) 
Chronic infarcts 
(# of animals) 
P-value 
In vivo MRI    
      LV wall volume (cm3) 63±15 (23) 85±13 (14) 0.00006 
      Infarct volume (%of LV volume) 25±6 (22) 15±5 (13) 0.00003 
      Animals with FPP defect 17 (21) 2 (13) 0.0007 
      FPP defect area (% of infarct area) 35±23 (21) 13±31 (13) 0.02 
      Animals with T2* signal void 5 (8) 3 (7) NS 
      Area of T2* signal void (% of infarct area) 24±22 (8) 15±19 (7) NS 
      CNR signal void vs. infarct area 34±11 (5) 23±6 (3) NS 
Ex vivo MRI    
      Area of T2* signal void (% of infarct area) 42±5 (8) 19±7 (11) 0.00001 
      CNR signal void vs. infarct area 17±9 (8) 14±8 (11) NS 
      CNR cells (4x106) vs. infarct area 18±4 (4) 15±1 (3) NS 
 
myocardium, and areas of signal voids 34 +11 (n=5).  
In chronic infarcts, an area of signal voids could be identified in three out of 
seven animals, comprising 15 +19% of the infarct area. MO was identified in two out of 
13 animals, comprising 13 +31% of the infarct area (P=0.0007 and 0.02 vs. 1 week, 
respectively; Table 1). Infarct size was 15 +5% (P=0.00003 vs. 1 week; n=
 
13). CNR 
between remote myocardium and areas of signal voids was 34 +21 and between 
infarcted, non-haemorrhagic myocardium, and areas of signal voids was 23 +6(n=
 
3).  
 
Ex vivo MRI and histology  
 
In subacute infarcts, the ex vivo high-resolution scans showed rings of magnetic 
susceptibility-induced signal voids on T1W and PDW scans (Figure 3). The size of the 
signal voids increased with a  
longer TE (T1-T2*W). The rings surrounded large hyperintense areas on T1W scans, 
which appeared hypointense on T2W and PD-T2*W scans. At histology, these rings of 
signal voids corresponded with blue deposits on PB staining and surrounded large 
areas of erythrocytes. 
In chronic infarcts, ex vivo scans showed magnetic susceptibility-induced 
signal voids on T1W, PDW, T2W, and T1-or PD-T2*W scans throughout the infarct 
area (Figure 4). Hyperintense areas were observed on T1W scans, which appeared 
hypointense on T2W and T1-or PD-T2*W scans (data not shown). Furthermore, 
hyperintense areas were observed on T2W scans, which appeared hypointense on T1W 
scans (data not shown). At histology, areas of signal voids matched the pattern of blue 
haemosiderin deposits after PB staining (Figure 5). No correlation was found with 
collagen, fat, or calcium deposits.  
Total haemorrhagic areas at mid-papillary level as a percentage of the total 
infarct area as determined by T2*W MRI were significantly larger in subacute than in 
chronic infarcts (P=0.00001; n=8 and 11, respectively; Table 1).  
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Figure 3 Ex vivo scans 1 week after infarction using different types of tissue contrast: T1W, PDW, T2W, 
and T2*W with a TE of 5, 20, or 60 ms (TE5, TE20, or TE60, respectively). Either a GE or an SE sequence 
was used. A ring of black signal voids is identified best in the T1W scan with a TE of 20 ms (T1–T2*W). It 
corresponds with the blue haemosiderin deposits in the PB image. The ring surrounds a hyperenhanced 
area on T1W scans, which is hypoenhanced on SE/T2 and PD-T2*W scans, corresponding with 
methaemoglobin within intact erythrocytes.  
 
Post-mortem injections with iron oxide-labelled cells could be located in remote, non-
infarcted myocardium. CNR between depots of 4x106 
 
labelled cells and infarcted, non-
haemorrhagic myocardium was 18 +4 in subacute infarcts (n=4) and 15 +1 in chronic 
infarcts (n=
 
3; Table 1). This was comparable with the CNR between haemorrhage-
induced signal voids and infarcted, non-haemorrhagic myocardium in subacute 
infarcts (17 +9; n=8) and chronic infarcts (14 +8; n=
 
11; Table 1). As a cause, in the 
infarct region, none of the injection sites could be reliably located and discerned from 
haemorrhage-induced signal voids (Figure 6). 
 
Discussion  
 
Myocardial infarct reperfusion and haemorrhage  
Reperfusion of MI is known to induce progressive MO, also described as the ‘no-
reflow’ phenomenon.19 
 
As shown in both animal and clinical studies, MO is followed 
by the development of haemorrhage, probably due to loss of microvascular 
integrity.20,24 
 
The extent of the haemorrhagic area has been shown to correlate with 
the size of MO,20 
 
which was also observed in the present study.  
 
Haemorrhage and MRI appearance  
Few studies have been performed to evaluate the extent of the haemorrhagic area after 
reperfusion of MI using MRI.24-26 One study demonstrated the presence of 
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haemorrhage by SE imaging within 72 h after reperfused MI in dogs.25 Hypointense 
lesions corresponding with haemorrhage were found in 14 out of 16 animals. These 
lesions were not found in non-reperfused animals. Furthermore, in two clinical 
studies, MRI was performed shortly after infarct reperfusion. The first study of 24 
patients using GE and contrast-enhanced imaging showed hypointense areas within 
the infarct region in 38% of patients by both techniques.24 In the second study, 39 
patients were imaged using a T2*W GE sequence and haemorrhage could be identified 
as a hypointense zone within the infarct region in 33% of patients.26 Because the two 
latter studies were done in patients, no histological comparison was possible. 
Furthermore, MRI was performed, on average, 6 days after MI, which is much shorter 
than the follow-up of 5 weeks used in the present study.  
 
 
Figure 4 Ex vivo scans 5 weeks after infarction using various types of tissue contrast as described in 
Figure 3. Magnetic susceptibility-induced signal voids are observed throughout the infarct. Their size 
increases with T2*-weighting (TE 20 ms). Furthermore, signal voids correspond with blue haemosiderin 
deposits in the PB image. Epicardial fat, indicated by F, causes a hyperintense signal on the T1W scan and 
a hypointense signal on T2 and T2*W scans. 
 
In contrast with intramyocardial haemorrhage, MRI appearance of intracranial 
haemorrhage has been given extensive attention.21 Intracranial haemorrhage causes 
accumulation of deoxyhaemoglobin within hours. Within days, deoxyhaemoglobin is 
oxidized to methaemoglobin, which causes T1 and T2 shortening owing to its 
paramagnetic properties and magnetic susceptibility effect.27-28 Therefore, the 
presence of methaemoglobin within intact erythrocytes causes hyperintense signals on 
T1W scans and hypointense signals on T2W scans, a pattern observed in the present 
study in subacute infarcts. With further degradation, haemosiderin deposits are 
formed,21 which remain chronically present.29 Haemosiderin has a high 
magneticsusceptibility effect and thereby causes T2 shortening, resulting in signal 
voids on T1W, T2*W, and T2W images surrounding the brain haemorrhage from 2 
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weeks onwards, the so-called ‘ring’ pattern. In the present study, the same ring pattern 
was observed in subacute infarcts in the ex vivo scans. This difference in time course 
might be due to the higher in-plane resolution of ex vivo scanning, allowing early 
detection of such a pattern.  
 
 
Figure 5 A tissue block from the infarct border of a 5-week-old infarction was scanned at high-resolution 
ex vivo.(A) shows the VK (calcium) and VG’s (collagen) staining. Red staining corresponds with 
collagenous (scar) tissue. Yellow staining corresponds with muscle fibres. Black calcium deposits were not 
observed in this section. In (B), a serial section is shown after PB staining. (C) shows the corresponding 
slice from the MRI T2*W data set. (D) shows the same section as in (B); however, blue regions are 
artificially enhanced. MRI signal voids correspond with blue haemosiderin particles and not with calcium, 
fat, or collagenous tissue. (E) shows the same section as in (B) at higher magnification. Blue haemosiderin 
deposits can be appreciated. (F) shows a serial section after HE staining. (G) shows the corresponding 
region in the image of (A). Area of signal voids corresponds with blue haemosiderin deposits in (E). (H) 
shows the boxed region in (F) at higher magnification; haemosiderin deposits are visible as brownish 
particles (black arrows). Bar indicates 4 mm in (A–D), 400 mmin (E–G), and 40 mmin (H) 
 
Iron oxide-labelled cell detection by MRI  
Detection of iron oxide-labelled cells within MI has been described for mice9,10 and 
rabbit11 models. Recently, several studies showed the feasibility of using iron oxide-
labelled cells for clinically relevant, catheter-based delivery and cell tracking within MI 
in pigs. Infarcts were created by permanent coil occlusion16,17 or a 60–90 min balloon 
occlusion, followed by reperfusion of the infarct artery.12,13,15 Cells were injected 
immediately after infarction12,14 
 
or into 1-day-,17 1-week-,15 or 4-week-13 
 
old infarcts.  
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Figure 6 The left panel shows the GE/PD-T2*W/TE20 scan, depicted in Figure 4, before injection with 
iron oxide-labelled cells. The middle panel shows the same slice after injection with 0.1, 1, or 4x106 iron 
oxide-labelled cells. The right panel shows a similar series of injections in remote, non-infarcted 
myocardium. Although the cell injections create larger areas of signal voids in the middle panel, their 
precise location cannot be determined because of the signal voids induced by the presence of 
haemoglobin degradation products. Bar indicates 0.5 cm 
 
None of these studies mentioned the presence of MO or haemorrhage within 
the infarct centre. In contrast, in the present study, MO was present in 17 out of 21 
animals in subacute infarcts, and signal voids were identified in all animals on the ex 
vivo scans corresponding with haemorrhage on histology. The high frequency of MO 
and haemorrhage could possibly be explained by the longer occlusion times used in 
our study (i.e. 2 h vs. 60 or 90 min),12,13,15 approximating the time to reperfusion in the 
clinical setting more closely. The frequency of MO in the present study is indeed 
comparable with the frequency in patients reperfused early after MI.22 Despite the 
longer occlusion times, it has been shown that haemorrhage already occurs in the pig 
heart after coronary occlusions more than 45 min.30 
In a previous study, examining iron oxide-labelled cell detection in a mouse 
cryoinfarction model,10 the presence of ‘spontaneous’ signal voids within the infarct 
region was discussed. These signal voids were attributed to necrosis and fibrosis 
within the infarct scar. However, a recent study showed that cryoinfarction results in 
large areas of haemorrhage,31 which have most likely caused those signal voids. 
Furthermore, the problem of those spontaneous signal voids was purportedly solved 
by using a combination of PD-and T2*-weighted scanning: the areas with signal voids 
that were exclusively due to the tissue lesions would lead to similar signal void sizes in 
both imaging modalities. In contrast, the size of the signal voids generated by the pre-
sence of labelled cells was proposed to increase on T2*-weighted scans, thereby 
making unequivocal detection possible. However, Figures 3 and 4 clearly illustrate 
that the usefulness of this method could not be demonstrated in the present study, as 
the size of the haemorrhage-induced signal voids increased with a longer TE.  
In studies of spinal cord regeneration by transplanted iron oxide-labelled 
cells,32.33 interference of haemorrhage with cell detection has been described as an 
important confounding factor. In one study, the discrimination between cells and 
haemorrhage was made by assessing the ‘blooming’ effect induced by iron oxide-
labelled cells, where the distortion of the magnetic field occurs over a greater area than 
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the presence of the contrast agent.32 
 
In another study, the use of imaging sequences 
less susceptible to haemorrhage-induced signal voids was proposed as a solution.33 
For cell detection in vivo, a certain number of labelled cells are necessary to 
obtain sufficient contrast with background tissue. For MI, the smallest number of cells 
needed for detection was reported to be 105 cells/150 mL,14 generating signal void 
volumes of 0.36 cm3. This study however was performed in a model of permanent 
occlusion in pigs. In three studies of porcine, reperfused infarct models, the number of 
cells per injection exceeded 28x106.12,13,15 In the present study, the haemorrhage-
induced signal voids in the in vivo scans had a mean total size of 0.53 +0.51 cm3 in 
subacute infarcts, and MRI of haemorrhage within reperfused MI therefore would 
possibly obscure detection of cell groups of 105 cells. Furthermore, CNR of signal voids 
identified on the T2*W in vivo scans were similar to the values previously reported for 
groups of iron oxide-labelled cells using similar scanning sequences.14 Finally, the ex 
vivo injections of iron oxide-labelled cells in the present study generated signal voids 
with a CNR similar to the haemorrhage-induced signal voids, thereby interfering with 
detection of the injected cells.  
The presence of haemorrhage and visualization with longer TEs are important 
in relation to the injection route, as visualization of labelled cells was reported with 
local injections,12-17 although intracoronary injections have been used in most human 
studies.3 Using iron labelling to track these cells, which will presumably spread over a 
larger area, requires sequences with long TE, and the artefacts described in the 
present study are to be expected.  
 
Study limitations  
Because it is a very subjective process to match the image locations of in vivo scans 
with the locations of ex vivo scans on the basis of anatomical landmarks only, and 
because the slice thickness of in vivo scans was 6 or 8 mm compared with 0.8 mm of 
ex vivo scans, we chose to describe in vivo and ex vivo findings separately. Therefore, 
our data do not allow for a direct comparison between in vivo and ex vivo scans.  
In the present study, a model of reperfused MI was used, causing large areas of 
haemorrhage. Therefore, it is not clear whether there is a difference in haemorrhage-
induced artefacts in reperfused vs. non-reperfused infarcts in porcine models in vivo, 
although in similar canine models, no haemorrhage was observed when perfusion was 
not reinstated.25 
Only intramyocardial injections were performed in the present study using 
fixed, iron oxide-labelled cells, which were imaged after tissue preparation. Future 
studies are required to investigate whether haemorrhage-induced signal voids cause 
similar interference with cell detection after intracoronary injection in vivo. 
 
Conclusion  
The present study demonstrates that haemorrhage in reperfused MI produces MRI 
signal voids, which may interfere with reliable tracking of iron oxide-labelled cells.  
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Coronary heart disease and heart failure continue to be significant burdens to 
healthcare systems in the Western world and are predicted to become so in emerging 
economies. Despite mixed results in both experimental and clinical studies, stem cell 
therapy is a promising option for patients suffering from myocardial infarction or 
patients with chronic heart failure after myocardial infarction. However, many issues 
in the field of cellular cardiomyoplasty still need to be resolved. This thesis describes 
the experiments performed in a pre-clinical model in swine with reperfused 
myocardial infarction aiming at addressing several of these issues. 
 
Chapter two of this thesis shows that infarct size in swine can be measured 
accurately with multislice computed tomography, as compared to the “golden 
standard” histology.  This study showed that myocardial viability can be assessed with 
multislice computed tomography. Furthermore, since we used magnetic resonance 
imaging in chapter three and four, we showed that for purposes of infarct size 
assessment multislice computed tomography compares well with magnetic resonance 
imaging, which is described in chapter three. Measurement of infarct size in patients 
with acute myocardial infarction is clinically relevant because infarct size is predictive 
of left ventricular function and geometric configuration and, hence, long-term clinical 
outcome. Information on infarct size obtained with multislice computed tomography 
would enhance the diagnostic armamentarium of physicians who lack access to 
cardiac magnetic resonance imaging or encounter patients who have contra 
indications to undergo magnetic resonance imaging. 
 
The review of umbilical cord blood derived cells in the fourth chapter of this 
thesis shows a great potential of these cells to regenerate damaged myocardium. These 
cells can easily be obtained in large numbers and are not harvested from diseased 
individuals, therefore they have a great differentiation and proliferation capacity. 
Moreover, they do not raise ethical difficulties question, as do embryonic stem cells. In 
chapter five, the effect of umbilical cord blood cells is assessed with magnetic 
resonance imaging in a porcine model of myocardial infarction. There was no positive 
effect on left ventricular function or infarct size four weeks after injection of 
intracoronary administration of the umbilical cord blood cells, which what not very 
surprising since only a few of the injected cells survived. Therefore, the immunogenic 
status of these cells is not fully understood yet. However, this study shows that 
cultured umbilical cord blood cells should be used with caution when applied 
intracoronary, since their large cell size result in occluded blood vessels, thereby 
causing micro infarctions. Hence, it cannot be excluded that a possible positive effect 
of the umbilical cord blood derived cells was obscured by the induction of micro 
infarctions caused by the mode of administration. Therefore intracoronary application 
is not suitable for these cells. Although intracoronary injection is an easy and less 
invasive technique to administer cells post myocardial infarction, intramyocardial 
injection was shown to result in positive effects by Kim et al. 
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In contrast to the cells used in the initial experimental rodent studies, bone marrow 
derived mononuclear cells are the most common used cells in clinical trials. In chapter 
six the capacity of mononuclear cells and unselected bone marrow in a pre-clinical 
porcine model of reperfused myocardial infarction is evaluated. Our model closely 
mimics the clinical setting of myocardial infarction with regards to the route of 
administration and timing of stem cell therapy given in clinical trials. Four weeks after 
treatment with mononuclear cell injection a decrease in infarct size is observed as 
measured with magnetic resonance imaging. This was not observed after injection of 
unselected bone marrow. Histology showed that there was a trend towards more 
calcifications in the infarct area after the injection of unselected bone marrow. 
However, there was no beneficial effect of mononuclear cell or unselected bone 
marrow therapy on left ventricular function after myocardial infarction. Our results 
after mononuclear cell injection do not differ from those of the clinical trial performed 
in Leuven, Belgium by Janssens et al. 
 
All clinical trials used the method of intermittent balloon occlusion during 
intracoronary injection of cells through the wire lumen of the balloon catheter, based 
on the assumption that this would yield increased adhesion of the injected cells to the 
vascular wall during the no-flow period, thereby leading to a higher cell engraftment. 
However, in our previous studies we used a selective probing injection catheter 
without interruption of blood flow. Therefore, we tested these different injection 
techniques in chapter seven. We observed no differences in the number of bone 
marrow mononuclear cells engrafted in the myocardium when applied through these 
two catheters (probing or balloon catheter). Therefore, the lack of effect on left 
ventricular function of bone marrow derived mononuclear cells in our study (which 
was described in chapter six), cannot be explained by the injection technique used. 
 
 Since cultured umbilical cord blood cells can cause micro infarctions when 
administered intracoronary in healthy myocardium (chapter five), we investigated in 
chapter eight whether cultured bone marrow derived mononuclear cells could cause 
micro infarctions four days after injection in healthy myocardium. We found that this 
was the case for cultured cells, but not for freshly isolated cells. Cultured cells are 
larger in size compared to freshly isolated cells, which result in the obstruction of the 
microcirculation. Although clinical trials suggest that intracoronary stem cell injection 
is safe, cultured stem cells should be used with caution when applied intracoronary.
  
 The labeling of injected cells with iron to be able to track them in vivo with 
magnetic resonance imaging is assessed in chapter nine. This study showed that due 
to the hemoglobin breakdown products containing iron which is present in 
hemorrhagic areas in the reperfused infarct, iron labeling of intramyocardially 
injected cells is not suitable to track the stem cells after injection.  
 
Future directions 
Future studies are required to investigate whether hemorrhage induced signal voids 
cause similar interference with cell detection with magnetic resonance imaging after 
intracoronary injection in reperfused myocardial infarctions or after injection in non-
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reperfused infarcts. Gadolinium may be a more suitable marker than iron to track cells 
in vivo with magnetic resonance imaging in reperfused myocardial infarctions. 
It should be further investigated what the effect of injection of cultured cells is, 
when applying a different mode of administration, for example intramyocardial cell 
injection. 
The effect of the stem cells used in our model seems to be disappointing 
compared to earlier study results in small rodents. It is possible that in our model 
bone marrow derived mononuclear cells will have a positive effect on left ventricular 
function in time. Therefore, in new experiments, swine should be monitored for a 
longer follow-up time, e.g. 2, 3, 6 and 12 months. For these experiments miniature 
swine should be used. 
 Differentiation of bone marrow derived stem cells in vitro towards 
cardiomyocytes is an option to enhance the effect of stem cell therapy in large 
mammals. However, it should always be tested whether these cultured cells induce 
microinfarctions when applied intracoronary. Pre-differentiation into 
cardiomoyocytes might prevent the differentiation of injected cells into fibroblasts or 
inflammatory cells. The pre-differentiation might replace scar tissue by viable 
cardiomyocytes, and this might enhance the effect on infarct size on left ventricular 
function in vivo after injection. However, if the new cardiomyocytes are not able to 
survive in ischemic tissue, it should be investigated whether additional cytokine 
injections are needed to induce angiogenesis in the infarct tissue to enhance cell 
survival. 
Patients benefit from optimal pharmacological treatment after myocardial 
infarction. Over time, ejection fraction will increase and infarct size will decrease in 
patients suffering from myocardial infarction due to remodeling which is influenced 
by optimal pharmacological treatment. Therefore, in a pre-clinical porcine model of 
myocardial infarction the combination of optimal pharmacological treatment and 
stem cell therapy could be tested to evaluate the additional effect of stem cell therapy 
on the recovery of function, infarct size and the remodeling after myocardial 
infarction.  
However first, in animal models, it is necessary to determine the optimal cell 
number required to obtain optimal effects of the cells on infarct size and left 
ventricular function. It should be investigated how to access the cells (e.g. bone 
marrow aspiration versus cytokine mobilization), and whether they should be 
expanded ex vivo. Second, it should be determined which cell type will have maximal 
clinical effects. Third, the optimal delivery method will have to be determined. Finally, 
understanding the mechanism of cardiac regeneration in animals will shed a light on 
the optimal therapy for patients. The potential effect of stem cell therapy in patients 
should finally be assessed in large, randomized, placebo-controlled, double-blind 
clinical trials. 
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Ondanks vele tegenstrijdige resultaten in zowel experimentele als klinische studies is 
stamcel therapie een veelbelovende optie voor patiënten met een myocard infarct, 
mede omdat er weinig alternatieve behandel methoden zijn voor patiënten met 
hartfalen. 
 
 In hoofdstuk twee van dit proefschrif is aangetoond dat je met “multislice 
computed tomography” nauwkeurig infarct grootte kan bepalen in varkens, dit is 
vergeleken met infarct grootte gemeten met histologie. Dit is de eerste studie die 
aantoont dat je met behulp van  “multislice computed tomography” myocardiale 
viabiliteit kan meten. Aangezien het bepalen van infarct grootte van een acuut 
reperfusie infarct met behulp van “magnetic resonance imaging” ook nog onduidelijk 
was, is in hoofdstuk drie ook aangetoond dat “multislice computed tomography” ook 
goed te verglijken is met “magnetic resonance imaging”, die we in hoofdstuk vijf en zes 
hebben gebruikt, als het gaat om infarct grootte. 
 
 In het review verhaal over navelstreng bloed cellen in hoofdstuk vier van dit 
proefschrift wordt de potentie van deze cellen om een infarct te regeneren duidelijk. 
Deze cellen kunnen makkelijk in grote aantallen gekweekt worden en ze zijn niet 
geoogst van zieke donoren, waardoor ze een grote differentiatie en delings capaciteit 
hebben. Bovendien zijn er geen ethische bezwaren tegen het gebruik van deze cellen 
zoals bij embryonale stamcellen. In de studie beschreven in hoofdstuk vijf is met 
behulp van “magnetic resonance imaging” het effect van  navelstreng bloed cellen 
bekeken in een varkensmodel met een myocard infarct. Er bleek geen positief effect te 
zijn op linker ventrikel functie of infarct grootte vier weken na injectie van de 
navelstreng bloed cellen, wat niet onverwacht was aangezien er maar een paar cellen 
overleeft waren. Hieruit bleek ook dat de immunogene status van deze cellen nog niet 
volledig is begrepen. Bovendien laat deze studie  zien dat je voorzichting moet zijn bij 
intracoronaire toediening van gekweekte navelstreng bloed cellen, omdat ze door de 
cel grootte bloed vaten kunnen verstoppen, wat kan leiden tot microinfarcten.  
In tegenstelling tot de cellen die de eerste experimentele knaagdier studies 
gebruikten, zijn mononucleaire cellen uit het beenmerg de meest gebruikte cellen in 
klinische studies. In hoofdstuk zes wordt de capaciteit van deze cellen in een pre-
klinisch varkens infarct-reperfusie model geëvalueerd. Ons model immiteert de 
klinische bepalingen van een myocard infarct en de route van toediening en het 
tijdstip van stamcel therapie in klinische studies. Vier weken na behandeling is er een 
verkleining van het infarct, gemeten met behulp van “magnetic resonance imaging”, 
waarneembaar. Er was echter geen effect van deze cel therapie op de linker ventrikel 
functie na het hartinfarct. 
 
 In alle voorgaande studies hebben we een probing katheter gebruikt om de 
cellen intracoronair toe te dienen, maar in de klinische studies is een ballon catheter 
gebruikt. Alle klinische studies gebruiken de onderbroken balloon occlusie tijdens cel 
injectie door het lumen van de ballon met de achterliggende gedachte dat de cellen 
sneller aan de vaatwand hechten tijdens deze periode zonder bloedstroom, wat zou 
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leiden tot een verhoogd aantal cellen dat in het infarct blijft hangen. We hebben in 
hoofdstuk zeven deze verschillende injectie katheters getest. Er was echter geen 
verschil in het aantal beenmerg mononuclaire cellen in het hart na injectie door deze 
twee katheters. 
Omdat gekweekte navelstreng bloed cellen micro infarcten veroorzaken na 
intracoronaire injectie in gezond hartweefsel, hebben we in hoofdstuk acht onderzocht 
of gekweekte mononuclaire cellen uit het beenmerg ook mirco infarcten veroorzaken, 
vier dagen na injectie in gezond hartweefsel. Dit blijkt het geval te zijn voor de 
gekweekte cellen, maar niet voor vers geїsoleerde cellen. Het moet nu verder 
onderzocht worden wat het effect is van  een ander route van toediening, bij voorbeeld 
intramyocardiaal, voor gekweekte cellen. 
 
 De mogelijkheid om geїnjecteerde cellen met ijzer te labelen en in vivo te 
volgen met behulp van “magnetic resonance imaging” is bepaald in hoofdstuk negen. 
Door het in het reperfusie-infarct al aanwezige ijzer, blijkt ijzer-labeling geen goede 
optie om stamcellen te volgen na injectie. 
 
Toekomstige studies 
Voor het labelen van cellen moet in de toekomst worden onderzocht of wellicht 
gadolinium een betere methode is. 
Tevens moet worden onderzocht of er na langere vervolging van mini-varkens 
wel een verbetering in linker ventrikel functie optreedt na injectie van beenmerg 
mononucleaire cellen. 
Pre-differentiatie van de te injecteren cellen in een cardiovasculair fenotype 
zou er ook toe kunnen leiden dat er wel een verbetering in linker ventrikel functie 
optreedt na injectie van deze cellen na een myocard infarct. 
Omdat patiënten profiteren van een optimale behandeling met medicijnen na 
een infarct, moet het onderzocht worden in een groot proefdier model wat het extra 
positieve effect van stamcellen bovenop de conventionele medische behandeling is. 
Uiteindelijk zal stamcel therapie in patiënten moeten worden onderzocht in grote, 
gerandomiseerde, placebo-gecontroleerde, dubbel-blinde studies. 
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